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Abstract 
NF-κB, a potent pro-inflammatory cellular transcription factor, is an 
inhibition target for many viruses, including the prototypic poxvirus member, 
vaccinia virus (VACV).  However, infection of HEK293T cells with the attenuated 
Modified Vaccinia Virus Ankara (MVA) no longer inhibits NF-κB activation, due to 
the absence of various host range and immunosuppressive genes in this strain.  
The work presented here focused on investigating the viral molecular mechanism 
responsible for the activation of NF-κB. 
To that end, we found that infection with MVA in the presence of AraC, a 
drug that inhibits viral DNA replication and intermediate and late gene 
expression, results in NF-κB nuclear translocation.  However, under conditions 
where either viral entry is blocked, the virions are inactivated, or viral mRNA 
synthesis is prevented, NF-κB remains inactive in virus-infected cells.  Thus, 
early viral gene transcription is responsible for MVA-triggered NF-κB activation.   
To identify the viral ORF(s) whose products activate NF-κB during MVA 
infection, we first tested a VACV plasmid library to identify which viral ORF could 
activate a NF-κB-controlled firefly luciferase gene.  We then utilized chemically 
synthesized siRNAs, testing the effect of silencing each of the viral genes 
individually on MVA-induced NF-κB activation in these cells.  Three viral genes 
(C11R, E7R, and A35R) have been identified whose silencing can prevent MVA-
induced ERK1/2 activation, which occurs upstream of NF-κB activation.   
iii 
The product of C11R, a viral growth factor protein, is capable of inducing 
ERK1/2 and NF-κB activation in the host 293T cells when it is expressed 
ectopically.  Furthermore, infection with a deletion mutant virus, MVAΔC11R, 
resulted in reduced ERK2 phosphorylation and NF-κB activation compared to 
cells infected with the parental MVA strain.  This reduction was observed in both 
293T cells and in keratenocyte cell line, HaCaT, indicating the C11R protein 
product modulates viral-induced NF-κB activation in multiple cell types.  Future 
work should focus on the molecular pathway utilized by C11 and the additional 
contributions the E7 and A35 proteins have in MVA-induced NF-κB activation. 
iv 
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Chapter I: Introduction 
 
An Introduction to Poxviruses 
The Poxviridae family is composed of a group of large DNA viruses 
capable of infecting a wide variety of invertebrate and vertebrate hosts.  Each of 
the members of this family have a single double-stranded DNA molecule, which, 
depending on the viral species, ranges from 130 kilobase pairs to over 300 
kilobase pairs in length. The genome encodes about 200 proteins and poxviruses 
encode many of the DNA replication and RNA transcription machinery necessary 
for the viruses’ life cycle.  Consequently, poxviruses are fairly independent of the 
host cell and replicate exclusively in the cell’s cytoplasm.  This characteristic sets 
poxviruses apart from most other DNA viruses, such as herpesviruses or 
adenoviruses, whose DNA replication takes place in the cell’s nucleus to allow 
the virus to take advantage of the cell’s replication machinery (Moss 2007).  
Current studies of poxviruses include their possible uses as oncolytic viruses, 
such as myxoma virus and vaccinia virus (Villa, et al. 2010), and as vaccine 
vectors for other diseases, such as HIV (Estaban 2009).  The Modified Vaccinia 
Virus Ankara (MVA), an attenuated poxvirus that induces NF-κB activation in 
infected cells (Oie and Pickup 2001), has been studied as a potential vaccine 
vector, as it is considered a safer alternative to the wild type vaccinia virus 
(VACV) strains (Sutter and Staib 2003).   Attention has also been given to variola 
and monkeypox viruses because of their potential use as a tool for bioterror and 
zoonotic infections, respectively.  Our lab is interested in studying how 
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poxviruses regulate immune responses, using MVA as our model system.  This 
information will help guide the development of poxvirus-based vaccines and 
therapeutics. 
 
The Poxvirus Life Cycle 
The poxvirus replication cycle has been largely studied using VACV, and it 
is thought that all poxviruses replicate similar to the strategy observed for VACV 
(Figure 1.1).   Poxvirus replication is temporal, and as a consequence, the block 
of one replication step will prevent all subsequent steps and inhibit replication.  
We used the application of this characteristic of poxvirus replication to determine 
the viral event responsible for MVA-induced NF-κB activation (Martin and Shisler 
2009).   
First, the virus binds to and enters the host cell.  The identification of 
possible binding receptors for these viruses has been challenging.  Poxviruses 
can enter most all cell types, even if a cell is not permissive for the virus to 
complete its life cycle.  So, unlike most other virus infections, in which host 
tropism is a result of the virus’ ability to gain entrance into the cell by the 
presence of a particular receptor, a poxvirus’ host range is determined by 
whether the life cycle can be completed in that cell (Moss 2007). Although no 
binding receptor on the host cell is known, there is some evidence that either 
glycosaminoglycans on the cell surface (Carter et al. 2005) or the cholesterol in 
lipid rafts play a role in viral entry (Chung et al. 2005). 
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While the exact mechanism involved in viral entry has not been 
elucidated, most evidence points toward the viral membrane fusing with the 
plasma membrane of the cell.  In fact, a number of viral proteins have been 
identified as belonging to an entry complex; for VACV, these include A16, A21, 
A28, G3, G9, H2, J5, and L5, with I2, F9 (Moss 2007) and L1 (Bisht et al. 2008) 
also involved.  All of these proteins are present in the viral membrane (Moss 
2007).  Exposure to antibodies against viral membrane proteins, such as L1, can 
bind to the viral proteins and prevent viral entry into the host cell (Ramsey-Ewing 
and Moss 1998). 
After viral binding and entry, early gene synthesis occurs. Poxvirus gene 
expression is temporal and occurs in three stages: early (maximal expression 
one to two hours post infection), intermediate (expression between two and three 
hours post infection), and late (expressed between three and 48 hours post 
infection). The machinery for early gene expression is packaged into virions, 
allowing early gene transcription to begin very quickly after viral entry. No introns 
are present in the poxviral DNA genome, and as such viral splicing is not 
observed.  Viral mRNA is poly-adenylylated and cap-methylated.  Early viral 
genes, which are estimated to account for half of all the viral genes, encode 
proteins involved in viral DNA replication and RNA expression, in addition to 
growth factors, immunoevasion, and intermediate transcription factors (Moss 
2007).  
After early viral gene transcription and translation occurs, the viral core is 
uncoated and DNA replication occurs in discrete areas of the cytoplasm called 
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virus factories (Moss 2007).  Poxvirus DNA replication is necessary for 
transcription of both intermediate and late genes.  Therefore, inhibition of viral 
DNA synthesis, such as with cytosine arabinoside (Ara C), blocks the 
transcription of intermediate and late genes, leaving early gene expression 
unaffected (Keck, et al. 1990). While the exact mechanism for this occurrence is 
not known, this event provides a reliable method to discern whether a poxviral 
gene is expressed early in infection.   
Intermediate viral gene expression follows viral DNA replication.  Only a 
small number of viral genes are expressed at the intermediate time, and they 
include transcription factors for late gene expression.  Most late gene products 
are either virion structural proteins, involved in viral morphogenesis, or are 
proteins that will be packaged into virions for the virus’ use after it infects another 
cell, such as early transcription factors and RNA polymerase. (Moss 2007)  
Virus assembly occurs in the cytoplasm in the virus factories.  Distinct 
stages of viral morphogenesis have been observed via electron microscopy.  
First, half crescents composed of lipid bilayers form.  Next circular immature 
virions are observed, and an aggregate of nucleoproteins become enclosed in 
these structures.  The virions continue to mature, forming the brick or ovoid-
shaped form called the mature virion (MV), which is fully infectious.  The MV has 
an outer membrane that is consistent with a single lipid bilayer.  The MV is 
composed of an internal dumbbell shaped core, containing the virus’ genome, 
and two lateral bodies found next to the concave surfaces of the core. The core 
wall is also composed of a lipid membrane (Moss 2007).  
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The poxvirus virion has two variations, the mature virion (MV) and the 
extracelluar enveloped virion (EV). The majority of viral progeny are MV, which 
are released upon cell lysis.  The EV, which contains an additional outer 
membrane compared to the MV, is released from the cell throughout the 
infection.  EV that remains attached to the cell surface are referred to as cell-
associated virions (CV).  CV is involved in infecting neighboring cells while the 
EV infects cells farther away (Smith and Law 2004). Actin polymerization is 
involved in the release of EV.  Viral proteins A34, A33, and A36 are required for 
the observed actin polymerization and subsequent release. Of note, glycosylated 
proteins are only found in the outer membrane of the EV form of the virus and not 
in the MV membrane (Moss 2007). 
 
Poxvirus Classification 
Thus far, most of the discussion has been focused on VACV, however, the 
Poxviridae family contains a number of related viruses.  The Poxviridae family is 
subdivided into two subfamilies, which are segregated based on whether the host 
is an insect (Entemopoxvirinae) or vertebrate (Chordopoxvirinae) (Moss 2007).  
The Entemopoxvirinae subfamily, which contains three genera, infects various 
insect hosts.  Genus A of Entemopoxvirinae infects beetles of the Coleoptera 
order.  Genus B infects moths and grasshoppers, in the Lepidoptera and 
Orthoptera orders respectively.  Genus C infects midge flies of the Diptera order 
(Arif 1995).    
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VACV belongs to the second subfamily of Poxviridae, Chordopoxvirinae, 
whose member viruses infect vertebrate hosts.  Chordopoxvirinae is further 
divided into eight genera: avipoxvirus, which infects bird species; capripoxvirus, 
which infects ruminant animals; leporipoxvirus, which infects rabbit and squirrel 
species; molluscipoxvirus, which infects humans; orthorpoxvirus, which has a 
wide range of host species; parapoxvirus, which typically infects ruminant 
animals; suipoxvirus, which infects pig species; and yatapoxvirus, which infects 
primates. In addition, there are unclassified viruses in the chordopoxvirus 
subfamily, such as crocodilepox virus. The genera are defined based on 
genetics, morphology, and host range.  In addition, cross-reactivity is observed 
between the virus species in a genus. For example, infection with vaccinia virus, 
the prototypal member of the orthopoxvirus genus, will induce protection against 
infection with other orthopoxvirus species, such as variola virus.  However, 
infection with the pseudocowpox virus of the parapoxvirus genus would not 
protect the host from an orthopoxvirus infection (Damon 2007).   
 
Diseases Caused by Members of the Chordopoxvirinae  
Many of the Chordopoxvirinae members cause diseases that impact 
veterinary or human medicine.  Members of the parapoxvirus and capripoxvirus 
genera infect farm animals, such as sheep (orf virus, sheeppox virus), cattle 
(pseudocowpox virus), and goats (goatpox virus) (Damon 2007).  Furthermore, 
many of these viruses can cause zoonotic infections in humans. Indeed, the 
majority of Chordopoxvirinae members have a very wide host range, allowing 
 7 
them to produce a productive infection and cause disease in a variety of 
vertebrates.  For example, cowpox virus has a natural reservoir in rodents, but is 
also capable of infecting a variety of animals including cows, cats (Bonneleoh, et 
al. 2007), elephants (Hemmer, et al. 2010), and humans (Bonneleoh, et al. 
2007).  Not all poxviruses have a broad host tropism, however.  For example, the 
orthopoxvirus ectromelia virus replicates in murine cells and only causes disease 
in mice, with Balb/c mice being especially susceptible.   Myxoma virus of the 
leparipoxvirus genus, is limited to causing an infectious diseases in rabbits. And 
the lone member of the mullusipoxvirus genus, mulluscum contagiosim virus, and 
the orthopoxvirus variola virus cause disease in humans only (Damon 2007). 
Of the eight Chordopoxvirus genera, the Orthopoxvirus genus contains 
arguably the most well-known and studied poxviruses, including monkeypox 
virus, cowpox virus vaccinia virus and variola virus.  Monkeypox virus is endemic 
in Africa and can infect numerous species of animals, including rodents and 
primates.  Importantly, it can cause zoonotic infections in humans and can be 
spread via human-to-human contact.  The severity of the resulting disease 
depends on the subtype of monkeypox virus with which the individual is infected.  
There are two separate clades of the virus, a more virulent Congo Basin strain, 
which is associated with the human to human spread and occasional human 
mortality, and a West African strain that results in a less severe disease with no 
mortality (Damon 2007).  In 2003, animals carrying the West African monkeypox 
virus strain were transported from Ghana to the United States.  The virus was 
transferred to prairie dogs that were being sold as pets, which in turn infected 
 8 
their human owners.  The incident marked the first outbreak of monkeypox virus 
in the United States.   Because it was the less virulent West African strain, the 
outbreak was fairly easily contained (Sejvar, et al. 2004).   
Variola virus is the causative agent for smallpox.  Smallpox had a mortality 
rate as high as 30-40% and is considered one of the deadliest diseases in 
human history. The disease dates as far back as 3,000 years ago (McFadden 
2010).  Variola virus was generally transmitted via the respiratory route.  After an 
asymptomatic incubation period of approximately two weeks, the infected 
individual would present with the characteristic systemic rash, a high fever, and, 
to a lesser degree, vomiting and body aches. The rash-based lesions would 
increase in size until a pustule was formed generally about a week after the 
onset of symptoms.  Two weeks after the rash presentation, the lesions would 
generally be scabbed over and then slough off.  The severity of the rash varied 
amongst individuals, and different presentations were associated with different 
outcomes.  For example, the most severe presentations were the hemorrhagic 
and flat smallpox, which had a lethality of greater than 80%.   There are two 
forms of the virus: variola major and variola minor.  The higher mortality was 
associated with variola major, while variola minor had a mortality rate of less than 
1% (Damon 2007).   
In 1798, Edward Jenner performed the first vaccination against smallpox 
by using cowpox virus.  In the twentieth century the World Health Organization 
began a worldwide effort to promote smallpox vaccination, using VACV as the 
innoculum.  Because the virus is a sole human pathogen and therefore no other 
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reservoir of the virus is found in nature, variola virus was eradicated in 1980. At 
present, there are only two official holdings of the virus in the world.  The vaccine 
used to eradicate smallpox was originally cowpox virus and later VACV 
(McFadden 2010).  Today, VACV is still used as the vaccine against 
orthopoxvirus infections, such as monkeypox virus infections (Damon 2007). 
 
Vaccinia Virus 
Vaccinia virus is the prototypal orthopoxvirus.  It is the most studied of the 
poxviruses and was the first animal virus to be visualized via an electron 
microscope and cultured in tissue culture (Moss 2007).  The natural host for the 
virus in unknown, but wild-type VACV has a very wide host tropism. Due to it’s 
success as a vaccine against smallpox, much research has and continues to look 
toward using VACV as a vector against other pathogens, including HIV (Estaban 
2009) and malaria (Gilbert, et al. 2006).  Wild-type VACV is still used as the 
vaccine against orthopoxvirus infections.  Although wide spread smallpox 
vaccination is no longer required for the general public, military personnel, health 
care workers, and orthopoxvirus researchers still receive the vaccine.   
Unfortunately, human-to-human spread of VACV is possible until a scab forms 
over the vaccination spot.  Accounts of vaccinated individuals inadvertently 
infecting others have been reported (Paul, et al. 2010). In immunocompetent 
individuals, immunization with VACV results in a localized lesion at the site of 
inoculation.  However, if the person suffers from immunodefiecieny, eczema, or 
atopic dermatitis, there is increased risk of complications and systemic disease.  
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This can result in a number of presentations, such as eczema vaccinatum, 
generalized vaccinia, post vaccinial encephalitis, and ocular vaccinia.  
Progressive vaccinia is potentially fatal (Damon 2007).   
While VACV has the potential for these severe complications, its value as 
a vaccine and as a vaccine vector continues.  Attenuated VACV strains, such as 
MVA, are an attractive alternative to the wild-type strains for use as a vector 
against smallpox and other pathogens. MVA was created by the serial passaging 
of the parental chorioallantois vaccinia virus Ankara (CVA) over 500 times in 
chick embryo fibroblast cells (Meyer, et al. 1991).  As a consequence, MVA has a 
genome that is approximately 15% smaller and has lost 64 functional genes 
compared to its parental strain CVA (Meisinger-Henschel, et al. 2007).  The 
majority of the genes lost include those encoding immunoevasion and host range 
proteins.  MVA has a restricted host range compared to the wild-type VACV 
strains: it can no longer replicate in human cells, although it can still enter human 
cells and induce an immune response (Slifka 2005).   
 
Poxviral Immunevasion Strategies 
Poxviruses encode a number of immunevasion proteins to limit the host’s 
immune defenses and prolong infection.  Host defenses that poxviral infections 
attempt to modulate include, but are not limited to, apoptosis, the complement 
system, Interferon, Toll-Like Receptors, and the NF-κB pathway.  In fact, wild-
type VACV encodes six confirmed NF-κB inhibiting proteins, including A46 
(Gonzalez and Esteban 2010), A52 (Graham, et al. 2008), N1, B14 (McCoy, et 
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al. 2010), M2 (Hinthong, et al. 2008), K1 (Willis, et al. 2011) and K7 (Oda, et al. 
2009).  Recent evidence suggests there is at least one additional NF-κB inhibitor 
encoded in the wild type vaccinia virus, although it hasn’t been identified yet 
(Fagan-Garcia and Barry 2011).   MVA, in comparison, is lacking functional A52, 
M2, B14, and K1 of the NF-κB inhibiting proteins (Meisinger-Henschel, et al. 
2007).  Unsurprisingly, while infection with wild type strains of VACV does not 
result in activation of NF-κB, infection with MVA does activate NF-κB in infected 
cells (Oie and Pickup 2001).  How NF-κB is activated during an MVA infection is 
the focus of this study.  
 
NF-κB Pathway 
Nuclear factor κB (NF-κB) is a well-conserved transcription factor that is 
important for the immune system and development.  It was first identified in 1986 
for its involvement in the regulation of the transcription of the κ light chain in B 
cells (Sen and Baltimore).  NF-κB has since been shown to be expressed in a 
variety of cells, and is a transcription factor for a number of genes, including 
various pro-inflammatory genes, anti-apoptotic genes, growth factors, and 
developmental genes.  Disregulation of the NF-κB pathway is a factor in 
diseases, such as cancer, diabetes, and arthritis (Vallabhapurapu and Karin 
2009).  Its role in immune function is particularly important, as it control the 
expression of cytokines, MHC proteins, apoptotic factors, and cell adhesion 
molecules (Oeckinghaus and Ghosh 2009).  
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The mammalian NF-κB complex is a heterodimer or homodimer 
composed of Rel proteins, including RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50), 
and NF-κB2 (p100/p52).  An N-terminally located Rel homology domain (RHD) is 
found in the five Rel proteins.  This RHD is necessary for protein interactions, 
including dimerization, and DNA binding.  All Rel proteins form dimers, with 
p65/p50 heterodimers being the most abundant form (Hayden and Ghosh 2004), 
but many other dimer combinations have been observed.  p65, RelB, and c-Rel 
also contain a C-terminal transactivation domain (TAD) which is responsible for 
the NF-κB dimers’ capacity to induce transcription.  If an NF-κB dimer is 
composed of subunits that do not contain a TAD, then its binding to DNA results 
in transcription inhibition and can interfere with a transcriptionally active form of 
NF-κB binding to the DNA.  Presumably, each NF-κB dimer combination could 
have a different role and effect on the outcome of NF-κB activation.   A 
preference for different NF-κB binding sites and recruitment of different co-
activator proteins has been observed, although what specific role each dimer 
plays is not clear.  But it has been shown that certain NF-κB dimers are more 
prominent in certain cell types than others (Oeckinghaus and Ghosh 2009).  
There are two well characterized inducible NF-κB activation pathways:  
the canonical and non-canonical. In addition, constitutive NF-κB activation is 
observed in certain immune cells, such as mature B cells and macrophages, 
neurons, and cancerous cells.   For the inducible canonical pathway, NF-κB 
dimers are initially found in the cytoplasm, bound to an inhibitory protein known 
as IκB.  The IκB family contains seven proteins: IκBα, IκBβ, BcL-3, IκBε, IκBζ, 
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p100, and p105.  Of note, the p100 and p105 proteins, while technically IκB 
proteins, are cleaved to form the p52 and p50 NF-κB subunits mentioned above.   
Each of these proteins contains five to seven ankyrin repeat motifs, which are 
important for protein-protein interactions, including interacting with RHD of NF-κB 
(Oeckinghaus and Ghosh 2009).  IκBα is canonically associated with p65/p50 
heterodimers.  Upon activation, the IκB protein is phosphorylated by the IκB 
Kinase (IKK) complex (Hayden and Ghosh 2004); for IκBα, phosphorylation 
occurs on Serine residues 32 and 36.  The IKK complex is large (700-900 kDa) 
and the identities and stoichiometry of the members of the complex haven’t been 
completely defined.  However, there are three proteins that are required for the 
IKK complex to be functional.  These are the catalytic subunits, IKKα and IKKβ, 
and the regulatory subunit IKKγ or NEMO (Israel 2010).  For the canonical 
pathway, IKKβ is responsible for phosphorylating IκBα.  In the non-canonical 
pathway, IKKα is used to phosphorylate p100.  Many intracellular pathways 
converge on IKK phosphorylation (activation), including TLR, TNFR1, PKR, and 
TCR/BCR signaling (Vallabhapurapu and Karin 2009).  Thus far, IKK 
phosphorylation is thought to be through both autophosphorylation and through 
other kinases, such the NF-κB inducing kinase (NIK) or the TAK1 (Israel 2010).  
Once IKK phosphorylates IκB, the SCF ubiquitin ligase ubiquitinates the 
phosphorylated-IκB, leading to IκB’s degradation by the 26S proteosome.  The 
NF-κB dimers are then released and enter the nucleus.   For the canonical 
p65/p50 dimer, the Nuclear Localization Signal (NLS) on p65 is exposed after 
IκBα degradation, triggering NF-κB to relocate to the nucleus (Figure 1.2) 
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(Hayden and Ghosh 2004). The p50 NLS was always exposed, but because of 
the presence of the nuclear export signal (NES) of the IκBα protein the steady 
state localization of the NF-κB-IκBα complex is the cytoplasm (Vallabhapurapu 
and Karin 2009).    
The non-canonical pathway is activated in a similar manner to the 
canonical pathway.  IKKα, instead of IKKβ, is responsible for phosphorylating the 
IκB.  Unlike in the canonical pathway, where no single kinase is responsible for 
the activation of the IKK complex, the NF-κB Inducing Kinase (NIK) is necessary 
for IKKα activation.  IKKα then phosphorylates the IκB p100, which is normally 
associated with and helps stabilize RelB containing dimers.  p100 is converted to 
p52 when it undergoes partial degradation via the proteosome, resulting in the 
loss of the carboxy-terminal ankyrin repeats (Vallabhapurapu and Karin 2009).   
Once the NF-κB proteins translocate into the nucleus, the NF-κB dimers 
then bind to the DNA sequence GGGRNNYYCC (κB site), where N is any base, 
R is a purine, and Y is a pyrimidine (Leung, et al. 2004).  For maximal 
transactivation to be observed, the NF-κB subunits also undergo post-
translational modifications.  p65 can be phosphorylated at various sites, including 
Ser276 and Ser311 in the RHD domain and Ser529 and Ser536 in the TAD 
domain.  The phosphorylation of p65 at Ser276 results in a break of a connection 
between the c-terminal portion of p65 with its RHD, thereby allowing the RHD 
greater access to binding the DNA. p65 can also be acetylated at lysine residues 
122, 123, 218, 221, and 310.  The various modifications effect p65’s ability to 
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interact with various co-activators, such as p300, or the inhibitory IκB proteins 
(Oeckinghaus and Ghosh 2009). 
The termination of NF-κB signaling is less understood than it’s activation.  
The IκB genes contain the NF-κB binding sequence in their promoter sequences, 
and consequently, NF-κB activation results in a negative feedback loop.  The 
freshly synthesized IκB proteins enter the nucleus and bind NF-κB, removing the 
dimers from the DNA (Oeckinghaus and Ghosh 2009).  Additionally, p65 may be 
degraded after poly-ubiquination in the nucleus by PDLIM2 (Vallabhapurapu and 
Karin 2009). 
The NF-κB pathway is affected by a number of other cellular pathways. 
The BCR and TCR receptor-signaling pathway on B and T cells, respectively, 
lead to NF-κB activation.  Signaling through the T-cell receptor (TCR), the B cell 
receptor (BCR), the Toll-Like Receptor (TLR) and Interleukin 1 receptor (IL1R), 
Retinoic Inducible Gene 1 (RIG1), Protein kinase R (PKR), and Tumor Necrosis 
α receptor (TNFR) all lead to NF-κB activation (Vallabhapurapu and Karin 2009). 
A number of other pathways, including the mitogen activated protein kinases 
(MAPK) pathways, including ERK 1 and 2 signaling, can cross-react with the NF-
κB pathway. ERK1 and 2, as members of the MAPK, are serine-threonine 
kinases, and are involved in various biological processes including immune 
function.  MAPKs have a number of substrates, including transcription factors 
AP-1 and Elk1 (Pearson, et al. 2001). In some cases, ERK1 and 2 activation can 
result in NF-κB activation (Park, et al. 1993, Ghosh, et al. 2010).  Infection with 
MVA results in the activation of both the NF-κB and ERK1 and 2 pathways, with 
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the activation of ERK1 and 2 acting upstream of NF-κB in infected cells.  This 
has been observed in fibroblast cells, such as 293T cells (Martin and Shisler 
2009), and the monocyte cell line, THP-1 (Delaloye, et al. 2009). 
 
Viral Modulation of the NF-κB Pathway 
 With such a prominent regulatory role in the immune system, it is not 
surprising that many pathogens, including poxviruses, have evolved various 
mechanisms to modulate NF-κB activation.  Many viral pathogens express 
proteins capable of blocking the activation of NF-κB signaling.  Myxoma virus is a 
leporipoxvirus with a very restricted host range limited to rabbits.  In European 
rabbits, myxoma virus causes a fatal disease called myxomatosis.  The myxoma 
virus protein MNF, which is encoded by the M150R gene, is an IκBα homologue 
with nine ankyrin repeats.  MNF binds to and inhibits NF-κB (Camus-
Bouclainville, et al. 2004).  The protein product for M103R has also been 
identified as an NF-κB inhibitor capable of binding the p50 subunit of NF-κB 
(Rahman, et al. 2009).     
Adenoviruses are DNA viruses that express four NF-κB inhibitory proteins.  
There are over 50 serotypes of adenoviruses capable of causing disease in 
humans. Normally, adenovirus infections cause upper respiratory infections, 
however depending on the serotype of the virus, it can cause disease in the 
lower respiratory tract, the intestines, the liver, urinary tract or eye (Horwitz 
2004). The viral proteins E1A, and E3-14.7K interact with the IKK complex to 
prevent IκBα phosphorylation and subsequent degradation.  E3-10.4/14.5K 
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inhibits upstream of the canonical NF-κB pathway by preventing TNF-α induced 
NF-κB activation.  The E1B protein has also been reported to inhibit NF-κB 
activation (Hiscott, et al. 2006). 
Poliovirus, a picornavirus, causes poliomyletis.  Although the majority of 
infected individuals are asymptomatic, poliomyletis can affect the central nervous 
system, leading to paralysis (Farbu 2010).  Poliovirus blocks NF-κB activation by 
the virally encoded 3C protease, which cleaves the RelA subunit of NF-κB 
(Hiscott, et al. 2006).  
While some viruses inhibit NF-κB activation to avoid the resulting increase 
in expression of proinflammatory genes, other viruses activate NF-κB in order to 
use the resulting anti-apoptotic proteins being expressed to prolong the infection 
or to take advantage of NF-κB’s function as a transcription factor for enhancing 
the expression of viral proteins.  For example, some viruses incorporate NF-κB 
binding sites into the viral genome, thereby allowing one of the host cell’s main 
defense to drive viral gene expression.  The human immunodeficiency virus 
(HIV) is perhaps the most well studied virus that actively seeks to induce NF-κB 
in this way.  HIV, as a typical retrovirus, inserts its genome into the host DNA.   
The long terminal repeat (LTR) region of the HIV genome contains NF-κB 
binding sites; therefore, the activation of NF-κB serves to drive the transcription 
of HIV encoded genes.  The virally expressed Tat, Nef, and Gp120 proteins can 
all induce NF-κB activation to further enhance the transcription of the viral genes 
(Hiscott, et al. 2006).  Gp120 interacts with CD4 on helper T cells, thereby 
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activating NF-κB (Bren, et al. 2009), however, the exact mechanism of action for 
Tat and Nef activating NF-κB is unclear (Hiscott, et al. 2006).    
Constitutive NF-κB activation is associated with the development of 
certain cancers.  The Human T-cell Leukemia virus type 1 (HTLV-1), like HIV, is 
a retrovirus that activates NF-κB.  HTLV-1 infects T cells and is strongly 
associated with the adult T-cell leukemia (ATL).   The viral protein Tax is the 
main activator of NF-κB; it works by activating the IKK complex thereby inducing 
the constituitive phosphorylation of IκBα and IκBβ.  In addition, Tax can also be 
found in the nucleus where it directly interacts with NF-κB and helps recruit the 
co-activators, such as p300 (Hiscott, et al. 2006).   
As NF-κB can induce the expression of various anti-apoptotic proteins, its 
activation can also by advantageous to viruses that set up latent infections in the 
host cell.  Epstein-Barr virus  (EBV) and Human herpesvirus-8 (HH8) are both 
gamma herpesviruses with a host tropism toward epithelial and B cells.  Epstein-
Barr virus is associated with lymphomas such as Burkitt’s lymphoma and 
Hodgkin’s lymphoma, and carcinomas including gastric carcinomas.  HH8 is 
largely associated with the development of Kaposi’s sarcoma.  Like most of the 
herpesviruses, EBV and HH8 establish latent infections in the host cell, during 
which very few viral genes are expressed and the virus is not replicating.  One of 
the viral proteins expressed during a latent infection with EBV is the Latent 
Membrane Protein 1 (LMP-1), which is the main factor in the transformation of B 
cells in vitro.  LMP-1 activates NF-κB, which results in the expression of various 
anti-apoptotic proteins.  For HH8, it expresses multiple activators of NF-κB, 
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including vFLIP, ORF74, and K15.  vFLIP is expressed during latent infections; it 
binds to TRAF2 which leads to NF-κB activation.  ORF74 and K15 are 
membrane proteins that are expressed during the lytic phase of infection.  
ORF74 functions as a chemokine receptor, while K15 is similar to the EBV LMP-
1 protein.  For both EBV and HH8, the development of cancer is closely tied to 
the constituitive NF-κB activation seen in the infected cells (Hiscott, et al. 2006, 
de Oliveira, et al. 2010). 
Unlike EBV and HH8, human cytomegalovirus (HCMV), a beta 
herpesvirus, is not associated with the development of cancer.  While a high 
percentage of the population is latently infected with HCMV, it generally only 
causes disease in immunocompromised patients or in newborn children.   
Human cytomegalovirus expressed proteins IE1, US28, NS5A, NS5B, and StpC 
have all been shown to contribute to NF-κB activation, which contributes to the 
virus’ ability to sustain a long-term latent infection (Hiscott, et al. 2006). 
The two hepatitis viruses able to cause chronic hepatitis disease, Hepatitis 
B (HBV) and C (HCV), encode proteins that activate NF-κB.  Although the two 
viruses are not in the same family of classification, as HBV is a DNA virus of the 
hepadnavirus family and HCV is an RNA virus of the Flaviviridae family, they 
both produce similar clinical disease in infected individuals.  Both are able to 
cause chronic hepatitis (Waris and Siddiqui 2003).  To this end, the activation of 
the NF-κB pathway is necessary for the viruses’ ability to sustain a long-term 
infection.  The HCV core protein binds to the death domain of the TNF receptor 
(TNFR1), leading to NF-κB activation (Hiscott, et al. 2001), while the HBV HBx 
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protein activates NF-κB and the MAPK cascade through oxidative stress (Hiscott, 
et al. 2006, Waris and Siddiqui 2003) 
As discussed above, under certain circumstances, there are advantages 
for a virus to either activate or inhibit the NF-κB pathway.  Some viruses 
manipulate the pathway by both activating and inhibiting NF-κB.  For example, 
although the core protein of HCV induces NF-κB activation, the NS5A and NS3-
4A proteins expressed by HCV inhibit NF-κB activation.  NS5A inhibits signaling 
involving TRAF2, which is a component of the TLR pathway to NF-κB activation.  
NS3-4A cleaves the MAVS protein, which is a critical component of the RIG1 
pathway (Hiscott, et al. 2006). 
The segmented RNA virus, influenza A, encodes at least four proteins 
whose expression results in the activation of NF-κB.  These include the 
hemagglutinin (HA) protein, the matrix (M) protein and the nucleoprotein (NP), 
which all induce IKK activation, and the non-structural protein, NS2, which 
activates the RIG1 signaling.  The HA, M, and NP proteins accumulate in the 
endoplasmic reticulum (ER) and induce the ER overload response (EOR) which 
leads to the NF-κB activation.  While this activation may at first appear 
unintentional for the virus, as the main functions of the HA, M, and NP proteins is 
not to activate the NF-κB pathway, the activation results in increase viral titer 
(Ludwig and Planz 2008).  However, NS1 protein can also bind to dsRNA in 
order to reduce NF-κB activation; during the infection, NS1 does not entirely 
prevent NF-κB activation (Hiscott, et al. 2006). 
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The African swine fever virus (AFSV) is a member of the virus family 
Asfarviridae.  These viruses are large double-stranded DNA viruses that, like 
poxviruses, are able to replicate in the cell’s cytoplasm. ASFV infects pigs, 
causing a hemorrhagic disease that typically results in death.  It has a cell 
tropism of macrophages and monocytes.  Two well-studied ASFV proteins are 
the early protein A238L and the late protein A224L, both of which modulate the 
NF-κB pathway.  A238L is a homologue of IκBα and is capable of binding to the 
NF-κB subunits to prevent NF-κB nuclear translocation.  However A238L cannot 
be phosphorylated by IKK complex and as such is not degraded upon IKK 
activation.  In contrast, A224L is a known activator of NF-κB.  It is a homologue 
of the inhibitor of apoptosis proteins (IAP), which function as anti-apoptotic 
factors by inducing NF-κB activation and inhibiting the cellular caspases.  
Presumably A238L inhibits NF-κB, thereby allowing the virus to escape the anti-
viral response during the early stages of ASFV infection, while A224L activates 
NF-κB at the later stages of infection to prevent apoptosis and prolong the 
infection (Hiscott, et al. 2006).    
 
Vaccinia Virus Modulation of NF-κB 
As described above, vaccinia virus expresses a number of proteins 
capable of inhibiting NF-κB activation.  As a consequence, NF-κB activation is 
generally not observed in cells infected with wild type vaccinia virus.  However, 
infection with the attenuated vaccinia strain MVA does activate NF-κB(Oie and 
Pickup 2001).  While MVA is missing some of the NF-κB inhibitors found in the 
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wild type VACV, including A52, B14, M2, and K1, MVA still encodes the genes 
for the A46 and N1 proteins (Meisinger-Henschel, et al. 2007).  A46 and A52 
interupt the IL-1β and TLR signaling to NF-κB (Gonzalez and Esteban 2010).  M2 
interferes with ERK1 and 2 signaling and NF-κB activation (Hinthong, et al. 
2008).  K1 prevents PKR activation and subsequent NF-κB activation (Willis, et 
al. 2011). N1 and B14 are Bcl-2-like proteins, with B14 inhibiting IKK 
phosphorylation of IκB (McCoy, et al. 2010).   
We have found that MVA encodes at least one protein capable of inducing 
NF-κB activation.  The product of C11R is a highly conserved early orthopoxvirus 
protein (Kim, et al. 2004).  C11 is a secreted protein known as the vaccinia 
growth factor (VGF) that is a homologue of the human epidermal growth factor 
(EGF) (Stroobant, et al. 1985).  Like EGF, it can bind to the EGF receptor (King, 
et al. 1986) and induce downstream signaling, including activation of the ERK1 
and 2 pathways (Andrade, et al. 2004).  Although VGF is not required for vial 
replication, the loss of VGF for wild type VACV results in reduced titers (Buller, et 
al. 1988). 
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Figures 
 
Figure 1.1. Vaccinia Virus Replication 
(adapted from Moss 2007). After the virus binds to and enters the cell, early gene 
transcription and protein synthesis occurs, followed by DNA replication.  
Intermediate and late gene transcription and protein synthesis occurs after DNA 
replication. 
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Figure 1.2. Canonical NF-κB activation pathway. 
Various signaling pathways can lead to the activation of NF-κB.  The IKK 
complex phosphorylates the inhibitory IκB, which is then degraded.  The NF-κB 
dimers then enter the nucleus of the cell, binding to conserved κB consensus 
sequences in the cellular DNA. 
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Chapter II: Early Viral Protein Synthesis is Necessary for 
NF-κB Activation in Modified Vaccinia Ankara (MVA)-
Infected 293 T Fibroblast Cells1 
 
Introduction 
Nuclear factor-κB (NF-κB) is a conserved eukaryotic transcription factor 
that is important for the immune system; it controls the expression of cytokines, 
MHC proteins, apoptotic factors, and cell adhesion molecules (Hoffmann, Natoli, 
and Ghosh, 2006). The canonical pathway triggering NF-κB activation is well-
characterized (Gilmore, 2006). Prior to activation, the p65/p50 heterodimeric NF-
κB complex is inactive in the cytoplasm, bound to its inhibitory protein, IκBα. 
Diverse events, such as virus infection, will activate the I kappa kinase complex 
(IKK) complex. Once IKK phosphorylates IκBα (DiDonato et al., 1997; Mercurio 
et al., 1997), IκBα is degraded (Baldi et al., 1996; Chen et al., 1995). The NF-κB 
NLS is then exposed and NF-κB relocates to the nucleus, where the transcription 
factor binds to a conserved DNA sequence to regulate 
gene expression. 
 The control of NF-κB activation during a natural virus infection can have 
great consequences (Hiscott et al., 2006). NF-κB inhibition, for example, is 
detrimental for a host, by virtue of viral proteins dampening components of the  
1Martin, S., and Shisler, J. L. (2009). Early viral protein synthesis is necessary for NF-
kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells. 
Virology. 390: 298-306. 
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innate and specific immune responses. In contrast, virus-induced NF-κB 
activation may be beneficial to the host because anti-viral immune responses to 
neutralize virus infections are activated. The effect of the virusmediated NF-κB 
activation is well-documented for cells infected with vaccinia virus, a virus that is 
highly similar to variola virus and an effective vaccine against smallpox (Moss, 
2007). An attenuated vaccinia virus, such as the modified vaccinia Ankara (MVA) 
strain (Mayr, Hochstein-Mintzel, and Stickl, 1975), induces NF-κB activation in 
host cells, whereas wild-type vaccinia strains do not (Oie and Pickup, 2001; 
Shisler and Jin, 2004). Wild-type vaccinia viruses utilize myriad mechanisms to 
inhibit NF-κB activation, including the synthesis of proteins that inhibit Toll-like 
interleukin-1β receptor- and tumor necrosis factor receptor-induced signaling 
(Alcami et al., 1999; Alcami and Smith, 1992; Bowie et al., 2000). However, the 
molecular mechanism responsible for MVA-induced NF-κB activation is 
unknown. The elucidation of this viral mechanism is important information when 
understanding how MVA regulates immune responses in vivo, and in considering 
the design of future MVA-based vaccines against smallpox or other infectious 
diseases. To this end, the stage of the MVA lifecycle responsible for activating 
NF-κB was identified in the 293T fibroblast cell line. Using molecular and 
pharmacological inhibitors, it was found that virus binding to or entry into host 
cells was not sufficient to trigger the activation of this cellular transcription factor, 
nor did Toll-like receptor signaling appear to be important for the MVA 
phenotype. Instead, viral protein expression was required for the NF-κB nuclear 
translocation in the 293T fibroblast cell line. Poxviral gene expression is 
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temporal, and ORFs are grouped into early, intermediate or late genes, based on 
promoter sequences and time of expression during infection (Moss, 2007). MVA 
infections under conditions preventing intermediate or late gene expression did 
not ablate NF-κB or ERK2 activation, suggesting that early gene expression is 
responsible for this phenotype. 
 
Materials and Methods 
Cells and viruses. 
The human kidney fibroblast HEK293T (293T) and baby hamster kidney 
(BHK-21) cell lines were obtained from the American Type Culture Collection 
(ATCC). All cells were cultivated in Eagle's minimal essential medium (EMEM) 
supplemented with 10% fetal calf serum (FCS; Hyclone), referred to as complete 
medium. MVA is an attenuated strain of vaccinia virus (Mayr, Hochstein-Mintzel, 
and Stickl, 1975). MVAΔE3L, an MVA-based virus in which the E3L ORF has 
been deleted (Ludwig et al., 2005), was a gift from Dr. Gerd Sutter (Paul-Ehrlich 
Institut). MVAΔE3Lwas amplified in BHK-21 cells, while MVA was amplified in 
primary CEF cells (Charles Rivers Laboratories). The Western Reserve (WR) 
strain of vaccinia virus, which was amplified in BHK-21 cells, is considered to be 
a wild-type strain of vaccinia virus. 
 
Conditions for virus infections. 
Subconfluent 293T cell monolayers in 6-well plates were either mock-
infected or infected with either WR, MVA or MVAΔE3L at 10 plaque forming units 
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(PFU)/cell, unless otherwise indicated. During this absorption phase, cellular 
monolayers and viruses were incubated in EMEM containing 1% FCS. After a 1 h 
incubation at 37 °C, viruscontaining medium was removed, and infected-cell 
monolayers were incubated in fresh, complete medium. In experiments where 
the activated form of ERK2 was detected, cells were instead incubated in 
medium containing 1% FCS for 24 h before infection, during the absorption stage 
of infection, and for the duration of infection. 
Infections proceeded for indicated amounts of time, and cytoplasmic and nuclear 
proteins were extracted as described below.  
To allow for virus attachment to, but prevent entry into, host cells, a 
previously described protocol was followed (Ramsey-Ewing and Moss, 1998). 
Briefly, the 1 h virus absorption (MOI=10) occurred at 4 °C, and cells were then 
incubated in pre-chilled medium containing anti-L1R antibodies (1:5000 dilution; 
a gift from Dr. Jay Hooper, United States Army Medical Research Institute for 
Infectious Diseases) or antibodies not reactive to the L1 protein (murine IgG; 
1:5000 dilution; Sigma Aldrich). After an additional 15 min incubation at 4 °C, 
cells were incubated in prewarmed medium at 37 °C for 4 h. As an alternative 
approach to prevent virus endocytosis, cells were instead incubated in 1% FCS 
EMEM containing dynasore (40 mM or 80 mM; Sigma Aldrich) for 30 min prior to 
infection. The drug remained present in medium during the adsorption phase of 
virus infection (MOI=10) and for the duration of infection. Cytoplasmic and 
nuclear proteins were extracted as described below.  
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To decrease viral gene expression, MVA particles were incubated in PBS 
containing 10 µg psoralen/ml (Sigma Aldrich) and subsequently exposed to 
ultraviolet (UV) radiation for 5 min. These conditions, according to a previous 
report, would greatly inhibit viral gene expression (Tsung et al., 1996). Next, 
treated virions were incubated with cellular monolayers for 1 h at 37 °C at an MOI 
of 10. Virus containing medium was removed and replaced with EMEM. An 
alternative approach to inhibit viral protein expression was to incubate cells with 
cordycepin (40 µg/ml; Sigma Aldrich) for 30 min before infection. This drug was 
also present during the adsorption stage of infection and for the duration of the 
infection. Cytoplasmic and nuclear proteins were extracted as described below.  
To inhibit intermediate and late gene expression, cells were incubated in 
medium containing 40 µg/ml cytosine arabinoside (AraC; Sigma Aldrich) for 30 
min. The drug remained present in medium during the adsorption phase of virus 
infection, in which cells were infected with 10 PFU/cell, and for the duration of 
infection. Cytoplasmic and nuclear proteins were extracted as described below. 
 
Immunoblotting of cytoplasmic-extracted proteins. 
For all experiments, infected cellular monolayers were dislodged by 
scraping. Next, cells were collected by centrifugation (30 s at 10,000 x g). 
Supernatants were removed, and cells were lysed, and cytoplasmic proteins 
were collected as described previously (Gedey et al., 2006). The protein 
concentration of each sample was determined by using the BCA assay (Pierce). 
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An equivalent amount of protein (20 µg) from each sample was loaded into 
separate wells of SDS-12% polyacrylamide gels.  
Proteins were separated electrophoretically and then transferred to a 
polyvinyl difluoride membrane (PVDF; Millipore). Membranes were incubated in 
blocking buffer (TBS containing 5% milk and 0.1% Tween-20) for at least one 
hour. Next, membranes were incubated at 4 °C overnight in TBS-T (TBS 
containing 0.1% Tween-20 and 0.5% milk) containing the primary antibody 
below. After washing membranes in TBS-T to remove unbound primary 
antibodies, blots were incubated with secondary antibody consisting of either 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:10,000; Fisher 
Scientific) or HRP-conjugated goat anti-mouse IgG (1:5000; Fisher Scientific). 
The antigen-antibody reactions on each immunoblot (IB) were detected by using 
chemilluminescence and autoradiography. For all IBs, the Pierce Supersignal 
West Pico substrate was utilized, according to the manufacturer's directions. 
Primary antibodies included: rabbit antiphospho-ERK1/2 antiserum (1:1000; 
Santa Cruz Biotechnology), which interacts with the phosphorylated form of 
ERK2 and the highly similar ERK1 protein; rabbit anti-ERK1/2 antiserum (1:1000; 
Santa Cruz Biotechnology), which recognizes the ERK2 and highly similar ERK1 
protein; rabbit anti-vaccinia antiserum (1:1000; Accurate Antibody), which was 
raised against vaccinia virus strain Lister particles, and contains polyclonal 
antiserum recognizing vaccinia proteins that are present in a mature virions; 
rabbit anti-actin antiserum (1:1000, Fisher Scientific); mouse anti-E3L antiserum 
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(Weaver et al., 2007) (1:1000), a gift from Dr. Stuart Isaacs (University of 
Pennsylvania).  
For quantification of the phospho-ERK2 signals, X-ray films were digitized 
and analyzed by using densitometry, using the Scion Image software (Scion 
Corporation). The signals were quantified by using the “analyzing one-
dimensional electrophoresis gels” program of Scion Image, using the “GelPlot2” 
macro. This method was used to compare the ratio of the band density for 
phospho-ERK2 only within each film image, where the film exposure time to the 
immunoblot was identical.  A value for the phospho-ERK2-specific signal was 
computed by dividing the value of signal obtained from lanes containing virus 
infected cellular lysate by the value of signal from lanes containing lysates of 
mock-infected cells. In this fashion, the value obtained for mock-infected cells 
was equal to one, while values of signals from MVA-infected cells were 
expressed as a fold-increase of phospho-ERK2 over uninfected cells. 
 
Gel electromobility shift assays (EMSAs) of nuclear-extracted proteins.   
The method for isolating nuclear proteins from virus-infected cells was 
described previously (Gedey et al., 2006). The concentration of protein in each 
sample was determined by using the BCA Protein Assay Kit (Pierce). Five 
micrograms of each extract was incubated with 0.35 pmol of 32P-labeled double-
stranded oligonucleotides containing binding sites for the NF-κB transcription 
factor (Promega) in Gel Shift Assay System Binding buffer (Promega) as per 
manufacturer's directions. Some reactions also included excess molar amounts 
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of non-radiolabeled oligonucleotides that either contained or lacked NF-κB 
binding sites, or 1 µg monoclonal anti-p65 antiserum (Santa Cruz Biotechnology). 
Following incubation, reactions were resolved electrophoretically in a 6% 
acrylamide gel (Invitrogen) under nondenaturing conditions, using TBE buffer. 
Afterward, the gels were dried onto filter paper, exposed to a phosphorimager 
plate (Molecular Devices), and images were developed and analyzed using the 
ImageGauge and ImageReader programs, respectively (Fuji). 
 
Luciferase reporter assay. 
A luciferase reporter assay was utilized to quantitate NF-κB activation in 
cells that were infected with poxviruses, as previously described (Shisler and Jin, 
2004). For these assays, 50 ng pRL-null (Promega) and 450 ng pNF-κBluc 
(Stratagene) were transfected into subconfluent 293T cell monolayers in 12-well 
plates by using FuGene6 transfection reagent (Roche) according to the 
manufacturer's protocol. At 24 h post-transfection, 293T cell monolayers were 
either mock-infected or infected with MVA (MOI=10). Alternatively, cells were 
infected with MVA virions pre-treated with psoralen and UV, as described above. 
To inhibit intermediate and late viral gene expression, infections instead occurred 
in the presence of AraC, as described above. In a separate experiment to detect 
the effect of Toll-like receptor signaling on MVA-induced NF-κB activation, cells 
were cotransfected 50 ng pRL-null, 450 ng pNF-κBluc, and 1000 ng either 
pERK2DN (Gedey et al., 2006) or pMyD88DN (Nichols and Shisler, 2006). At 24 
h post-transfection, cells were infected with MVA (MOI=10) or incubated in 
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medium containing either 10 or 20 ng IL-1β/ml medium (Sigma). Regardless of 
these variations, all cells were harvested 4 h post-infection by scraping, collected 
by centrifugation 
(30 s at 14,000 x g), and resuspended in passive lysis buffer (Promega).   
For all luciferase assays, the resultant lysates were assessed for 
luciferase activities as described previously (Shisler and Jin, 2004). All assays 
were performed in triplicate. For each experimental point, firefly luciferase 
activitywas divided by sea pansy luciferase activity to correct for differences in 
transfection efficiencies. Resultant ratios were averaged and normalized to the 
appropriate control cells (mock-infected cells or cells co-transfected with 
pcDNA3.1, pNF-κBluc and pRL-null). The value for the control cells was taken as 
1. Results were displayed as relative fold change in luciferase activity as 
compared to either mock-infected cells or pcDNA3.1-transfected cells. Statistical 
significance was determined by using the Student's t-test. 
 
Results 
NF-κB and ERK2 activation occur early during MVA infection, and EKR2 
phosphorylation precedes NF-κB activation.   
It was shown previously that MVA infection of 293T cells results in host 
cell NF-κB activation (Oie and Pickup, 2001; Shisler and Jin, 2004). To 
determine when this event occurred during poxvirus infection, we detected NF-
κB nuclear translocation, a hallmark of NF-κB activation, in virus-infected cells by 
using EMSA. When NF-κB is present in the nuclear extracts, and therefore 
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active, it binds to radiolabeled oligonucleotides and retards their mobility. While 
there were multiple bands present in all lanes, one unique band was present in 
the lane containing extracts from infected cells harvested at 2–12 h post-infection 
(Figure  2.1A). This same band increased in intensity until 4 h post-infection, 
remained relatively high until 10 h post-infection, and then decreased in intensity 
at 12 h post-infection (Figure 2.1A). It was verified that the unique mobility-shifted 
band indeed contained the NF-κB complex: when antibody recognizing the p65 
subunit of NF-κB was present, and presumably binding to NF-κB, the unique 
band disappeared and a higher-mobility band appeared. The NF-κB containing 
band disappeared in reactions containing of non-labeled oligonucleotides 
possessing NF-κB binding sites, but remained when non-labeled 
oligonucleotides instead possessing the AP1 binding site were present. 
Activation of the ERK2 protein is necessary for MVA-induced NF-κB 
nuclear translocation in 293T cells (Gedey et al., 2006). Therefore, ERK2 
phosphorylation should temporally precede MVA-induced NF-κB activation. To 
verify this, the presence of the active, phosphorylated (phospho-) ERK2 was 
detected at different times post-infection by using immunoblotting. Indeed, ERK2 
activation occurred before NF-κB activation; a 42kDa phospho-ERK2 band was 
detected in cells harvested as early as 30 min post-infection (Figure  2.1B). 
ERK2 activation, as measured by the intensity of the phospho-ERK2-containing 
band, peaked between 3 and 4 h post-infection, paralleling maximal NF-κB 
nuclear translocation in MVA-infected cells. Finally, ERK2 phosphorylationwaned 
6 h post-infection, and was no longer detectable 8–12 h post-infection (Figure  
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2.1B), even though NF-κB was still present in the nucleus of virus-infected cells 
at these times (Figure  2.1A). The antiphospho-ERK2 antibody also cross-reacts 
with the highly similar phospho-ERK1 protein, as is evidenced by the presence of 
a higher molecular weight, 44 kDa band in most samples (Figure  2.1B). The 
differences in phosphorylated ERK2 levels were not due to uneven protein 
loading since similar amounts of ERK1 and ERK2 proteins were detected in each 
reaction (Figure  2.1B). The density of phospho-ERK2-containing bands was 
quantified by using densitometry. Values for phosph-ERK2-specific signals were 
computed by dividing the value of the signal obtained from lanes containing 
lysates from virus-infected cells by the value of the signal obtained from the lane 
containing lysates from mock-infected cells. The differences in phospho-ERK2 
band intensities were represented graphically, and mimicked the trends observed 
in the immunoblot in Figure  2.1B. When comparing the phospho-ERK2 levels, 
the density of the phospho-ERK2 band the lane containing lysates from mock-
infected cells was set at a value of “1,” and the value for other treatments (virus 
infection) was presented as fold-increases over the value obtained for mock-
infected cells. For this particular immunoblot, the phospho-ERK2 levels in cells at 
3 h post-infection is approximately 9-fold higher than that observed during mock 
infection.  
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MVA does not utilize the MyD88 accessory protein to activate NF-κB in 293T 
cells. 
MVA activation of dendritic cells (DCs) requires, in part, the Toll-like 
receptor 9 (TLR9), an intracellular molecule known to trigger NF-κB activation 
(Samuelsson et al., 2008). Since NF-κB activation is necessary for DC activation 
(Rowe et al., 2008), we queried if the TLR signal transduction pathway was 
responsible for MVA-induced NF-κB activation in 293T cells. To this end, 293T 
cells ectopically over-expressing dominant negative mutant MyD88 proteins were 
infected with MVA, and NF-κB activation was measured via a luciferase-based 
reporter assay, in which a luciferase gene is under the transcriptional control of 
an NF-κB promoter. Results are shown in Figure  2.2. Luciferase activity levels 
were increased about 7-fold in lysates from MVA-versus mock-infected cells, 
inferring that MVA activated NF-κB. As previously published (Gedey et al., 2006), 
the over-expression of a dominant negative ERK2 protein diminished luciferase 
activity. In contrast, luciferase activity levels in pMyD88DN-transfected cells were 
higher than those observed for either pERK2DN or untransfected cells, 
suggesting that MVA-induced NF-κB activation did not require MyD88-dependent 
TLR activation. To confirm that the dominant negative MyD88 protein was 
expressed at levels that were biologically significant, a separate set of pMyD88-
transfected cells were incubated with interleukin-1β (IL-1β), a cellular cytokine 
that utilizes the MyD88 accessory protein to activate NF-κB. As would be 
expected, IL-1β-mediated luciferase activity was greatly diminished in 
pMyD88DN-transfected cells versus pcDNA3.1-transfected cells. Notably, MVA-
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induced luciferase activity remained unaffected in pMyD88DN-transfected cells, 
inferring that the ERK2 activation pathway remained intact in these cells.  
 
Virus binding to the cell membrane and viral endocytosis is not sufficient to 
activate NF-κB.   
Since NF-κB activation and ERK2 phosphorylation occurred relatively 
early during virus infection, one of the following events was responsible: virus 
binding to the host cell, virus entry into the cell, early viral protein expression, or 
DNA replication. To test if virus binding to the host cell was sufficient to activate 
NF-κB, the virus adsorption stage of infection occurred at 4 °C and in the 
presence of anti-L1R antibodies. Infections then proceeded for 4 h at 37 °C. This 
treatment allows virus binding to the host cell, but prevents entry (Ichihashi, 
Takahashi, and Oie, 1994; Ramsey-Ewing and Moss, 1998). Under these 
conditions, there was a dramatic decrease in MVA-mediated NF-κB nuclear 
translocation as compared to MVA-infected cells incubated in medium lacking 
antibodies or in medium with antibodies not specific to vaccinia virus (Figure  
2.3A). As would be expected, NF-κB remained inactive if non-specific antibodies 
were present during mock infection or during infection with WR, a wildtype strain 
of vaccinia virus that inhibits host cell NF-κB activation (Shisler and Jin, 2004). 
Similar to Figure  2.1A, the addition of anti-p65 antibodies to reactions containing 
extracts from MVA-infected cells super-shifted the NF-κB-containing band, 
verifying the presence of NF-κB in the observed band.  
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The effectiveness of anti-L1 antibody treatment to prevent virus entry was 
measured indirectly, by detecting viral protein synthesis in lysates from infected 
cells (Figure  2.3B). When probing cytoplasmic extracts from WR- or MVA-
infected cells with polyclonal antiserum raised against whole vaccinia virions, 
several unique bands (110 kDa, 35 kDa, 27 kDa, 15 kDa) were present, 
indicating that the polyclonal anti-vaccinia virus antiserum recognized multiple 
vaccinia virus proteins. In comparison, these bands' intensities were greatly 
decreased when assaying lysates from anti-L1, MVA-infected cells (Figure  
2.3B), inferring that the anti-L1 treatment indeed impeded virus entry into cells. 
Since actin levels were similar in all samples, the differences in viral protein 
levels were not due to unequal protein levels in each reaction.  
It was reported recently that vaccinia virus penetration of the host cell 
occurs via a dynamin-dependent endocytosis pathway, an event inhibited by 
dynasore (Huang et al., 2008). As shown in Figure  2.3C, when virus infections 
occurred in the presence of dynasore, NF-κB no longer translocated to the 
nucleus, indicating that virus binding and endocytosis was not sufficient for virus-
induced NF-κB activation.  Detection of viral E3 protein, an early vaccinia protein 
expressed only after viral endocytosis, was utilized as a mechanism to indirectly 
confirm the effectiveness of dynasore treatment (Figure  2.3D). Indeed, the 
intensity of band representing the 20 kDa E3 productwas dramatically decreased 
when infections proceeded in the presence versus the absence of dynasore.  
It was expected that ERK2 would remain inactive when MVA infections 
occurred in the presence of dynasore.  As predicted, there was a decrease in 
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MVA-mediated ERK2 activation in the presence of dynasore, as measured by 
detection of phosphorylated ERK2 by immunoblotting (Figure  2.3D). When 
comparing the intensity of the phospho-ERK2 bands in this immunoblot by using 
densitometry, it was observed that the phospho-ERK2 levels in cells treated with 
40 µM dynasore was similar (approximately 1), regardless of whether cells were 
infected or mock-infected. While there was a slight increase in the phospho-
ERK2 levels in MVA-versus mockinfected cells in conditions in which cells were 
treated with 80 µM dynasore (1 versus 0.5), levels were still lower than those 
observed for MVA infection (approximately 2) in the absence of drug. For this 
immunoblot, the fold-increase in phospho-ERK2 levels in MVA infected cells was 
lower than that observed for Figure  2.1, and this may be due to the presence of 
DMSO. Detection of similar amounts of ERK1 and ERK2 proteins in each sample 
negated the possibility that differences in phospho-ERK2 levels were due to 
decreased amounts of proteins in each sample.  
 
Viral protein expression is necessary for MVA-induced NF-κB activation. 
Cordycepin is a nucleoside adenosine derivative that prevents the 
translation of poxviral mRNA (Esteban and Metz, 1973). Thus, its presence 
during infection would assess the role of viral proteins synthesis on MVA-induced 
NF-κB activation. Since NF-κB remained inactive when MVA infection occurred 
in the presence of cordycepin (Figure  2.4A), it was concluded that viral protein 
synthesis was necessary for NF-κB activation. At the concentration used for this 
experiment, cordycepin was effective at inhibiting viral protein expression: 
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immunoblotted viral proteins detected with antivaccinia or anti-E3 antiserum were 
decreased when infections occurred in the presence of cordycepin versus its 
absence (Figure  2.4B). Actin levels in each of the cytoplasmic lysates were 
equivalent, inferring that the differences in observed viral protein levels were not 
due to differences in protein levels loaded in each sample.   
To confirm the necessity of viral protein expression for MVA-induced NF-
κB activation, a separate experiment, using MVA virions pre-exposed to 
ultraviolet (UV) light and psoralen, was performed. The use of these two 
treatments results in virions that still bind to and enter the host cell, yet a majority 
of the viral genome is not expressed or replicated (Tsung et al., 1996). In 
comparison to cells infected with untreated MVA, UV/psoralentreated MVA no 
longer activated NF-κB (Figure  2.5A), confirming data in Figure  2.4A. When 
luciferase reporter assays were used as an alternative method to indirectly 
measure NF-κB activation, similar results were obtained. As shown in Figure  
2.5B, MVA infection of cells induced an increase in firefly luciferase activity 
approximately 7-fold greater than mock-infected cells, presumably reflecting NF-
κB activation. However, luciferase activity was decreased when cells were 
instead infected with psoralen/UV-inactivated MVA virions (Figure  2.5B), 
inferring that NF-κB was inactive under these conditions.   
Phospho-ERK2 was greatly decreased in cells infected with the treated 
virions as compared to those incubated with unmodified MVA (Figure  2.5C), a 
result that was predicted. Equivalent levels of unmodified ERK2, and the highly 
similar ERK1, were detected in each sample, indicating that the differences 
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observed for phospho-ERK2 levels were not due to differing protein levels 
present in each sample. The UV/psoralen treatment of MVA virions was effective 
for decreasing viral protein synthesis. As shown in Figure  2.5C, when 
expressing phospho-ERK2 levels graphically, by using densitometry to measure 
phospho-ERK2, it was observed that phospho-ERK2 levels were 30-fold higher 
in MVA-infected cells versus mock-infected cells. In contrast, phospho-ERK2 
levels were only 5-fold above mock-infected cells when MVA virions were pre-
treated with UV and psoralen. UV/psoralen treatment of MVA dramatically 
decreased the synthesis of the early E3L protein, and the L1R late protein was 
no longer detected under these conditions, indicating that the UV/psoralen 
treatment of virions was sufficient to greatly decrease early gene expression.  
 
Intermediate or late gene expression, but not early gene expression, is 
dispensable for MVA-induced activation of NF-κB and ERK2.   
Poxvirus gene expression is temporal, with early genes expressed before 
viral DNA replication, and intermediate and late genes expressed after viral DNA 
replication (Moss, 2007). To determine if intermediate and late proteins were 
dispensable for MVA-induced NF-κB activation, we infected 293T cells in the 
presence of cytosine arabinoside (AraC), a drug that prevents viral DNA 
replication, and subsequent intermediate and late gene expression.   
Under these conditions, the lack of intermediate and late protein 
expression did not affect the ability of MVA to activate host cell NF-κB at 4 h 
post-infection, since the nuclear translocation of NF-κB was still detected in 
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nuclear extracts (Figure  2.5A). Furthermore, NF-κB remained effective as a 
transcriptional activator of a luciferase reporter gene in MVA-infected cells, 
regardless of whether AraC was present or absent during infection (Figure 2.5B). 
Not surprisingly, virus-induced ERK2 phosphorylation was unaffected by the 
presence of AraC during infection (Figure  2.5C). The effectiveness of the drug in 
inhibiting intermediate and late protein expression is demonstrated in Figure 
2.5C, when immunoblotted lysates were probed for the presence of either an 
early product (the E3L product) or a late product (the L1R product).  When 
comparing lysates from cells infected in AraC-containing versus complete 
medium, there was a decrease in the amount of L1R product present, indicating 
a decrease in late protein synthesis. E3L protein expression was not affected by 
the presence of AraC, as would be predicted.  
As confirmation that late viral protein expression was dispensable for NF-
κB activation, 293T cells were instead infected with MVAΔE3L, a mutant MVA 
construct deleted for the early E3L ORF. As reported by Ludwig et al. (2006), 
infection of 293T cells with MVAΔE3L results in an abortive infection, in which 
candidate late proteins are not produced. Under these circumstances, NF-κB 
remained active in MVAΔE3L-infected cells, as detected by an EMSA (Figure  
2.6A). Importantly, the temporal regulation of NF-κB during MVAΔE3L infection 
was similar to that observed during infection with MVA, implying that the 
extended NF-κB activation observed during MVA infection was solely due to 
early gene expression. Since ERK2 activation is required for NF-κB activation 
(Gedey et al., 2006), it was not surprising to observe that phosphorylated ERK2 
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was detected in extracts from MVAΔE3L-infected cells (Figure 2.6B). As would 
be expected, the temporal activation of ERK2 was similar in MVAΔE3L- and 
MVA-infected cells. The density of phospho-ERK2-containing bands was 
quantified by using densitometry. Values for phosph-ERK2-specific signals were 
computed by dividing the value of the signal obtained from lanes containing 
lysates from virus-infected cells by the value of the signal obtained from the lane 
containing lysates from mock-infected cells. In this experiment, phospho-ERK2 
levels were highest at 1–3 h post-infection, with MVA infection inducing phospho-
ERK2 levels 3–5-fold above mock-infected cells. While this activation profile was 
slightly different than that observed for Figure 2.1, we still observed ERK2 
activation early during infection, and then waning at times later in infection for 
both experiments. Phospho-ERK2 levels in MVAΔE3Linfected cells were slightly 
lower than those of MVA-infected cells, inducing 2–4-fold above mock-infected 
cells. Regardless of virus used, phospho-ERK2 levels were similar to mock-
infected cells by 4 h postinfection. 
 
Discussion 
Modified vaccinia virus Ankara infection, unlike wild-type vaccinia strains, 
activates the cellular NF-κB transcription factor (Gedey et al., 2006; Oie and 
Pickup, 2001). The viral mechanism(s) responsible for this phenotype was 
heretofore unknown. Using several approaches, we identified that viral gene 
expression was required for this phenotype, with the expression of the early class 
of vaccinia ORFs correlating with MVA-induced NF-κB activation. Two 
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possibilities for this phenotype existed. First, the concomitant expression of all 
early proteins was activating NF-κB via mechanisms such the endoplasmic 
reticulum overload response (EOR) pathway. However, since MVA infection of 
293T cells did not trigger calcium release (data not shown), an event occurring 
during EOR activation (Kuang et al., 2005), this possibility was unfavorable. An 
alternative hypothesis is that the expression of an individual early viral protein 
activates NF-κB either directly or indirectly. Experimental approaches to test 
each of these theories are the subject of ongoing investigations.  
Recent studies have investigated the effects of MVA infection on DC 
activation. Dendritic cells (DCs) are potent antigen presenting cells to activate 
naive CD4+ and CD8+ T cells, making them important for the development of 
adaptive immune responses (Guermonprez et al.,2002). NF-κB activation is 
necessary for DC activation (Rowe et al., 2008). One prediction from our results 
is that early protein synthesis is also required for MVA-induced DC activation. 
This model is in agreement with a report that UV-inactivation of MVA does not 
enhance virus-induced DC activation (Samuelsson et al., 2008). However, DC 
activation with UV-treated MVA has also been documented (Drillien, Spehner, 
and Hanau, 2004; Waibler et al., 2007), in contrast to our findings reported here. 
Additionally, MVA activation of DCs utilizes the TLR9, an intracellular molecule 
known to trigger NF-κB activation (Samuelsson et al., 2008). However, the 
inhibition of TLR9-induced NF-κB activation, via over-expression of a dominant 
negative MyD88 protein, did not decrease MVA-induced NF-κB activation. 
Whether MVA possesses two different mechanisms for activating NF-κB in 
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fibroblasts (early protein synthesis required, TLR-independent) versus immune 
cells (early protein synthesis not required, TLR-dependent) is the subject of 
future studies. Yet another possibility is that UV irradiation of MVA is not as 
efficient for crosslinking the MVA genome as UV/psoralen treatment of MVA 
(Tsung et al., 1996). Thus, UV-irradiated MVA virions might allow for the 
transcription of viral ORFs, an event that would not occur with UV/psoralen-
treated MVA virions. Finally, these differences could be due to varying TLR 
protein expression levels in fibroblast versus immune cells.  
ERK2 and NF-κB activation occurred rapidly after virus infection, raising 
the possibility that proteins in the mature virion may activate NF-κB when the 
virus is intracellular. However, we observed two experimental conditions in which 
the inhibition of viral protein synthesis rendered NF-κB inactive in virus-infected 
cells (UV/psoralen treatment of virions and incubation of cells with cordycepin).  
These data support our position that nascent viral proteins are responsible for 
NF-κB activation.  
Curiously, NF-κB remained active in MVA-infected cells for an extended 
period of time. Although MVA infection of human monocyte-derived DCs 
upregulates IκBα gene expression (Guerra et al., 2007), it is likely that virus 
infection in 293T cells sequesters the auto-regulatory feedback loop for NF-κB. 
Whether these patterns remain present in all fibroblasts versus immune cells, 
and whether this trait possesses physiological relevance, is unknown. Equally 
unlikely is a late gene product prolonging NF-κB activation: cells infected with 
MVAΔE3L, a deletion mutant virus that no longer expresses intermediate or late 
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genes in 293T cells (Ludwig et al.,2005; Ludwig et al., 2006), have an NF-κB 
activation profile that is identical to that of MVA-infected cells. A current favored 
model for this prolonged activation is that a viral product actively synthesized 
throughout infection induces this phenotype. Yet another possibility is that an 
early protein that is stable throughout infection can activate NF-κB throughout 
infection. Data obtained using the MVAΔE3L virus for infection cannot rule out 
either of the above possibilities.  
Poxviruses are complex viruses that produce multiple immunoevasion 
products, with many of these products important for virulence (Moss, 2007). Data 
shown here indicate that vaccinia also expresses proteins to stimulate the 
immune response. Why the wild-type virus maintains multiple genes that encode 
proteins with opposing actions is an important conundrum, given the traditional 
idea that viruses are evolutionarily driven to minimize the number of genes they 
encode. This finding may indicate that temporal regulation of NF-κB activation is 
more important than overall inhibition of NF-κB during vaccinia virus 
pathogenesis, and leads to a new appreciation for the regulation of this 
transcription factor during a poxvirus lifecycle. Notably other viruses, such as 
herpes viruses, also express proteins that either activate or inhibit NF-κB (Hiscott 
et al., 2006), suggesting that control of this transcription factor by complex 
viruses is a common strategy for survival and pathogenesis. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.Temporal NF-κB nuclear translocation and ERK1/2 
phosphorylation during vaccinia infection. 293T monolayers were either 
mock-infected or infected with MVA (MOI = 10).  At the times indicated post-
infection, cells were collected and lysed, and cytoplasmic and nuclear extracts  
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Figure 2.1 (cont.) 
were isolated.  (A) 5 µg of nuclear-extracted proteins from each sample were 
incubated with 32P-radiolabeled oligonucleotides containing consensus NF-κB 
binding sites, and analyzed via an electromobility shift assay.  The location of the 
mobility-shifted band containing NF-κB is indicated by an asterisk (*).  For some 
reactions, the nuclear extracted proteins from MVA-infected cells (4 h post-
infection) were also incubated with excess amount of non-radiolabeled 
oligonucleotides containing either NF-κB binding sites (NF-κB) or lacking NF-κB 
binding sites (AP1), or with anti-NF-κB antibodies recognizing the p65 subunit of 
the NF-κB dimer (p65 Ab).  The super-shifted band containing anti-p65 is 
indicated by the “+” symbol.  (B) 20 µg of the cytoplasmically extracted proteins 
were electrophoretically separated via SDS-12% PAGE.  Proteins were 
transferred to PVDF membranes, and immunoblots (IBs) were subsequently 
probed with antiserum recognizing the phosphorylated forms of ERK2 and ERK1 
(p-ERK1/2) or the unmodified forms of ERK1 and ERK2 (ERK1/2).  Molecular 
weight markers (MW) in kDa are indicated on the left hand side of the 
immunoblot.  Densitometry analysis was performed to quantify the phospho-
ERK2 levels in the immunoblot.  The signal from the lane containing lysates from 
mock-infected cells was set as a value equal to one.  The amount of phospho-
ERK2 in lanes containing lysates from MVA-infected cells was graphically 
represented as a fold-increase above that observed for mock-infected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  MVA-induced NF-κB activation in cells expressing a dominant 
negative mutant MyD88 protein.  293T cellular monolayers were co-transfected 
with pRL-null, pNF-κBluc and either pERK2DN or pMyD88DN, as indicated.  At 
24 h later, cellular monolayers were either mock-infected or infected with MVA 
(MOI of 10).  An additional set of pMyD88DN-transfected cells was instead 
incubated with 10 ng or 20 ng IL-1β per ml medium for 4 h.  At 4 h post-infection 
cells were harvested, collected by centrifugation and incubated in passive lysis 
buffer.  Firefly and sea pansy luciferase activities were measured, and the  
resultant ratios were normalized to that value obtained using untreated, 
uninfected cells 
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Figure 2.3.  The effect of inhibiting virus entry, but not attachment, on MVA-
induced NF-κB activation and ERK2 phosphorylation.  (A and B) 293T 
monolayers were either mock-infected or infected with MVA or WR (MOI = 10).  
After a 1 h absorption period at 4°C, medium was replaced with ice-cold medium 
containing either mouse IgG or anti-L1R antiserum (L1 Ab) for 15 min at 4°C.  
Next, infections proceeded at 37°C for 4 h.  (C and D) 293T cells were incubated 
in medium either absent for or containing dynasore.  At 30 min later, cells were 
incubated with MVA (MOI = 10) in medium either containing or lacking dynasore, 
and infections proceeded with the drug present for 4 h.  For all figures, cells were 
harvested and lysed, and cytoplasmic and nuclear extracts were obtained as 
described in Figure 1.  (A and C) Nuclear-extracted proteins were incubated with 
32P-radiolabeled oligonucleotides containing consensus NF-κB binding sites,  
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Figure 2.3 (cont.) 
and NF-κB activation was analyzed by using an EMSA.  The NF-κB-containing 
band is indicated by an asterisk.  For some reactions, nuclear extracts from 
MVA-infected cells were incubated with an excess amount of non-radiolabeled 
oligonucleotides or antiserum as described in Figure 1.  A reaction containing 
loading buffer only is labeled as “NC.”  A super-shifted band is denoted by “+.”  
(B and D) Alternatively, cytoplasmically extracted proteins from each sample 
were analyzed by using immunoblotting.  Membranes were subsequently probed 
with the indicated primary antibodies.  Molecular weight markers (MW) are 
indicated on the left hand side of the immunoblot.  Densitometry analysis was 
performed to quantify the phospho-ERK2 levels in the immunoblot in Figure 3D.  
The signal from the lane containing lysates from mock-infected cells was set as a 
value equal to one.  The signal from lanes containing lysates from MVA-infected 
cells was graphically represented as a fold-increase above that observed for 
mock-infected cells.  Values obtained from cells incubated in medium containing 
dynasore were also compared to mock-infected cells. 
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Figure 2.4.  The virus-mediated NF-κB activation state in the presence of 
cordycepin.  293T cellular monolayers were incubated in medium either absent 
for or containing cordycepin (40 µg/ml).  At 30 min later, cells were either mock-
infected or infected with MVA (MOI = 10).  Where applicable, the drug was 
present in the medium during the adsorption stage of infection and for the 
duration of the infection.  At 4 h post-infection, cells were lysed, and proteins 
from either the cytoplasm or the nucleus were isolated.  (A) Nuclear-extracted 
proteins were analyzed for NF-κB activity by EMSA, as described in Figure 1.  
The location of mobility-shifted bands containing NF-κB is indicated by an 
asterisk.  For some reactions, nuclear extracts from MVA-infected cells were 
incubated with an excess amount of non-radiolabeled oligonucleotides or 
antiserum as described in Figure 1.  In one lane, only gel loading dye was added 
(NC).  (B) Cytoplasmic proteins (20 µg from each sample) were analyzed by 
using immunoblotting, as discussed in Figure 1.  IBs were probed with the 
indicated antibodies.  Molecular weight markers (MW) are indicated on the left-
hand side of the figure. 
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Figure 2.5.  The effect of either Ara C treatment of cells or psoralen/UV 
treatment of virions on MVA-induced NF-κB activation and ERK2 
phosphorylation.  (A and C) Cellular monolayers were either mock-infected or 
infected with MVA (MOI of 10) in medium absent for or containing 40 µg/ml Ara 
C.  Alternatively, some MVA virions were incubated in PBS containing psoralen 
(10 µg/ml) and subsequently treated with UV for 5 min before incubation with 
cellular monolayers (MOI = 10).  In all cases, at 4 h post-infection cells were 
harvested, collected by centrifugation and lysed, and cytoplasmic and nuclear 
proteins were isolated.  For (A), nuclear-extracted proteins were analyzed for NF-
κB activation by EMSAs, as described in Figure 1.  The location of mobility-
shifted bands containing NF-κB is indicated by an asterisk.  Some reactions 
contained nuclear extracts from MVA-infected cells and either anti-NF-κB 
antibodies (p65 Ab), or excess amounts of non-radiolabeled oligonucleotides 
containing NF-kB binding sites (NF-κB) or lacking NF-κB binding sites (AP1).  A 
super-shifted band is indicated by a plus sign.  A lane containing only loading 
buffer is labeled as NC.  (B) Subconfluent 293T cell monolayers were transfected 
with pRL-null and pNF-κBluc.  24 h later, cellular monolayers were either mock-
infected or infected with MVA (MOI of 10) as described in (A).  At 4 h post-
infection cells were harvested, collected by centrifugation and incubated in 
passive lysis buffer.  Firefly and sea pansy luciferase activities were measured, 
and the resultant ratios were normalized to that value obtained using untreated, 
uninfected cells.  (C) Cytoplasmic extracts from either mock- or virus-infected  
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Figure 2.5 (cont.) 
cells were analyzed for cellular and viral proteins as described in Figure 1.  IBs 
were probed for either the phosphorylated (p-ERK1/2), or unphosphorylated 
forms of ERK1/2.  Identical IBs were alternatively incubated with anti-E3L or anti-
L1R antiserum.  Molecular weight (MW) markers are on the left-hand side of the 
immunoblot.  Densitometry analysis was performed to quantify the phospho-
ERK2 levels in the immunoblot in Figure 5C.  The signal from the lane containing 
lysates from mock-infected cells was set as a value equal to one.  The signal 
from lanes containing lysates from MVA-infected cells was graphically 
represented as a fold-increase above that observed for mock-infected cells.  
Values obtained from cells incubated with UV/psoralen-treated MVA were also 
compared to mock-infected cells. 
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Figure 2.6.  The NF-κB activation and ERK2 phosphorylation states in cells 
infected with MVA viruses either lacking or containing the E3L ORF.  293T 
cell monolayers were either mock-infected or infected with either MVA (MOI = 10)  
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Figure 2.6 (cont.) 
or MVAΔE3L (MOI=10).  One hour after the absorption period, cells were 
incubated in fresh medium.  Cellular monolayers were incubated at 37°C for the 
indicated times.  Cells were lysed, and cytoplasmic proteins and nuclear proteins 
were isolated.  (A) Nuclear extracted proteins were analyzed for NF-κB nuclear 
translocation by using EMSAs as described in Figure 1.  The location of mobility-
shifted bands containing NF-κB is indicated by an asterisk.  For some reactions, 
nuclear extracts from MVA-infected cells were incubated with an excess amount 
of non-radiolabeled oligonucleotides or antiserum as described in Figure 1.  A 
super-shifted band containing NF-κB is indicated by a plus sign.  In one lane, 
only gel loading dye was added (NC).  (B) 20 µg cytoplasmically extracted 
proteins from each sample were analyzed by immunoblotting.  Membranes were 
probed with antibodies recognizing either the phospho- or unmodified forms of 
ERK1 and ERK2.  Molecular weight (MW) markers are indicated. Densitometry 
analysis was performed to quantify the phospho-ERK2 levels in the immunoblot 
in Figure 6B.  The signal from the lane containing lysates from mock-infected 
cells was set as a value equal to one.  The signal from lanes containing lysates 
from MVA- or MVAΔE3L-infected cells was graphically represented as a fold-
increase above that observed for mock-infected cells. 
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Chapter III:  The C11R Gene, which Encodes the 
Vaccinia Growth Factor (VGF), is Required for MVA-
Induced NF-κB Activation in 293T and Hacat Cells, but 
not THP-1 Cells 
 
Introduction 
  MVA is an attenuated vaccinia virus (VACV) that was created by serially 
passaging wild-type VACV in chicken embryo fibroblast cells over 500 times 
(Mayr, et al., 1975). MVA was used safely as a smallpox vaccine in the 1970s 
(Hochstein-Mintzel, et al.,  1972), and is advantageous as compared to wild-type 
VACV because it is replication-incompetent in all human cells tested (Blanchard, 
et al., 1998, and Carroll and Moss 1997). However, a drawback for its use as a 
smallpox vaccine is that higher or multiple doses of MVA are required to achieve 
the anti-VACV antibody response obtained with a single dose of wild-type VACV 
(Wyatt, et al. 2004). More recently, MVA was used as a vector for vaccines 
against a variety of infectious diseases of humans (AIDS, malaria) and wildlife 
(rabies)(Jacobs, et al. 2009).   
Wild-type VACV strains such as WR encode immunoevasion genes, 
whose products inhibit NF-κB, whereas these genes are missing from MVA 
(Antoine, et al., 1998, and Mohamed and McFadden. 2009). As a result, WR 
infection inhibits NF-κB, whereas MVA infection activates NF-κB (Oie and Pickup 
2001). While these data would suggest that NF-κB activation diminishes MVA’s 
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immunogenicity, one cannot regard this model as proven, because other 
profound genetic differences exist between WR and MVA. In comparison to WR, 
MVA is replication-incompetent (Carroll and Moss 1997) and MVA lacks myriad 
immunoevasion genes, whose products dampen other immune responses 
(Antoine, et al., 1998).   
To more accurately evaluate the relationship between NF-κB and the 
immunogenicity of MVA, our rationale is to identify the viral component(s) 
responsible MVA-induced NF-κB activation and use this information to create 
MVA constructs that lack NF-κB activating capacity. Some of these components 
are already known. For example, in the 293T human fibroblast cells, MVA-
induced NF-κB activation requires the expression of the early class of poxviral 
genes (Martin and Shisler 2009). Next, early gene product(s) either directly or 
indirectly stimulate activation of the MEK1 mitogen-activated protein kinase 
(MAPK), resulting in extracellular-signal-related kinase 2 (ERK2) activation, an 
event that is upstream of and necessary for MVA-induced NF-κB activation 
(Gedey, et al., 2006, and Martin and Shisler 2009).  
The epidermal growth factor receptor (EGFR), when interacting with its 
cognate EGF, triggers receptor activation to induce proliferation, cell survival and 
NF-κB activation (Prenzel et al., 2001). The EGFR stimulates these myriad 
events via distinct upstream signal transduction events. For example, EGFR-
Sos-Ras-Raf-MEK1 activation activates the ERK1/2 proteins, resulting in cellular 
proliferation (Prenzel, et al. 2001). EGFR autophosphorylation can also stimulate 
phosphoinositide 3-kinase (PI3K) and NF-κB-inducing kinase (NIK), and it has 
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been reporter that EGFR-induced NIK activation results in NF-κB activation 
(Habib, et al., 2001). 
The goal of this study was to identify viral protein(s) that are upstream 
activators of this ERK2-NF-κB activation pathway, using 293T cells as a model 
system. Data indicate that the EGFR initiates this pathway during MVA infection. 
While the EGFR is known to activate ERK2 via the Sos-Ras-Raf-MEK1 pathway, 
we show here that a Ras85 and Raf-independent pathway trigger EGFR-induced 
NF-κB activation (Prenzel, et al., 2001). MVA, like all other orthopoxviruses, 
encodes vaccinia growth factor (VGF), a homolog to EGF (Twardzik, et al., 
1985). Either silencing or removal of the gene encoding VGF (C11R) resulted in 
an MVA virus that was compromised in its ability to activate ERK2 and NF-κB. 
This phenotype was observed during infection of 293T and Hacat keratinocyte 
cells, but not in the monocytic THP-1 cell line, suggesting that MVA infection 
activates NF-κB via cell-type dependent pathways. These findings characterize a 
mutant MVA that can be used as a tool to ask how MVA-induced NF-κB 
activation affects the immunogenic properties of MVA-based vaccines. 
 
Materials and Methods 
Cells, viruses and plasmids.  
Cell lines used in this study were: the human kidney fibroblast HEK293T 
(293T), Chinese hamster ovarian cells (CHO K1), human transformed 
keratinocytes (Hacat), and human monocytic leukemia cells (THP-1).  Except for 
THP-1 cells, cell lines were cultivated in Eagle’s minimal essential medium 
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(EMEM) supplemented with 10% fetal calf serum (FCS; Hyclone), referred to as 
complete medium. THP-1 cells were cultivated in RPMI 1640 medium 
supplemented with 10% FCS. MVA is an attenuated strain of vaccinia virus, and 
the Western Reserve (WR) strain of VACV is considered to be a wild-type strain 
of VACV (Mayr, et al., 1975).  
An MVA virus in which the C11R gene was replaced by a gene encoding 
the green fluorescent protein (GFP) (MVAΔC11R) was created by homologous 
recombination in primary chicken embryo fibroblasts (CEFs)(Hinthong et al., 
2008). MVAΔC11R progeny viruses were selected based on their ability to stably 
express GFP, and plaque purified four times. After plaque purification, the 
absence of contaminating parental virus DNA and the presence of the GFP in the 
C11R region was verified by PCR analysis of viral genomes, using primers that 
specifically bind to each of the regions flanking the C11R gene. Stocks of pure 
recombinant MVAΔC11R were propagated in CEF cells.  
Plasmid pC11R, in which the VACV C11R gene was inserted into 
pcDNA3.1, was described previously (Tscharke et al., 2006). Plasmids encoding 
dominant negative forms of Raf (pRafDN) and Ras (pRasDN) were a gift from Dr. 
Larry Karnitz (Mayo Clinic, Rochester, MN). pNIKDN is a plasmid encoding a 
dominant negative NIK protein (pNIKDN). 
 
Measurement of NF-κB activation by using a firefly luciferase reporter assay.  
A luciferase reporter assay was utilized to quantitate NF-κB activation in 
infected or transfected cells, as previously described (Gedey, et al., 2006). For 
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assays involving virus infection, subconfluent 293T, Hacat or CHO K1 cellular 
monolayers in 12-well plates were transfected with 50 ng pRL-null (Promega) 
and 450 ng pNF-κBluc (Stratagene), using FuGene 6 transfection reagent 
(Roche) as per manufacturer’s instructions. Transfections proceeded for 24 h 
prior to virus infection. To evaluate the role of the EGFR during MVA infection, 
transfected cells were incubated in DMSO-containing medium either lacking or 
containing AG1478 (Sigma Aldrich; 50 µM) for 30 min prior to infection, with the 
compounds remaining present in medium throughout the infection.  To evaluate 
the role of Raf and Ras in MVA-induced NF-κB activation, cells were co-
transfected 50 ng pRL-null, 450 ng pNF-κBluc, and 1000 ng either pRafDN, 
pRasDN, pNIKDN or pcDNA3.1 for 24 h prior to virus infection. Regardless of 
these differences, for all luciferase assays involving virus infections, cells were 
either mock-infected or infected with MVA or MVAΔC11R at an MOI of 10 plaque 
forming unites (PFU)/cell, unless stated otherwise. At 6 h post-infection (pi), 
unless stated differently, cellular monolayers were lysed in passive lysis buffer 
(PLB; Promega) for 15 min, as per manufacturer’s suggestions.   
To test the effect of ectopic expression of the viral gene C11R on NF-κB 
controlled luciferase activity, subconfluent 293T cells were co-transfected 50 ng 
pRL-null, 450 ng pNF-κBluc, and either 1000 ng pcDNA3.1 or 1000 ng pC11R. 
At 24 h later, cellular monolayers were lysed in PLB as described above. 
For all luciferase assays, the resultant lysates were assessed for 
luciferase activities as described previously (Shisler and Jin 2004). All assays 
were performed in triplicate. For each experimental point, firefly luciferase activity 
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was divided by sea pansy luciferase activity. Resultant ratios were averaged and 
normalized to the appropriate control cells (mock-infected cells or cells co-
transfected with pcDNA3.1). The value for the control cells was set to 1. Results 
were displayed as relative fold change in luciferase activity as compared to 
values from control cells. Statistical significance was determined by using the 
Student’s t-test. Values where p < 0.05 were considered statistically significant.  
 
Western immunoblotting.  
A previously published protocol was used to extract cytoplasmic proteins 
from virus-infected or transfected cells (Shisler and Jin 2004). To evaluate the 
role of Raf and Ras signaling in MVA-induced NF-κB activation, 293T cells were 
transfected with 1000 ng of pRafDN, pRasDN, pNIKDN or pcDNA3.1 (-) for 24 h 
prior to virus infection. For infected cells, monolayers of 293T, CHO K1 or Hacat 
cells were either mock-infected or infected with MVA, MVAΔC11R or WR. When 
using THP-1 cells for these experiments, cellular suspensions were incubated in 
medium containing phorbol myristate acetate (PMA; 100 ng/ml; Sigma Aldrich) 
for 24 h prior to infection with MVA, MVAΔC11R or WR (MOI = 5). Infections 
proceeded for 4 h, and cells were harvested, collected by centrifugation, and 
then lysed in CE buffer (Oie and Pickup 2001). In an experiment to evaluate the 
role of the EGFR in ERK1/2 activation, 293T cells were incubated with DMSO-
containing medium that either lacked or contained AG1478 (Sigma Aldrich; 50 
µM) for 30 min prior to and throughout infection.   
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In some experiments, the transcriptional silencing of the C11R gene was 
used to study how the absence of the VGF protein affect ERK1/2 activation. In 
this case, subconfluent monolayers of 293T cells were plated into 24-well plates. 
24 h later, cells were transfected with a solution containing siRNA molecules 
specific for 4 different regions of a viral mRNA. The final concentration of each 
siRNA in cellular medium was either 25 or 50 nM, such that the total final 
concentration of siRNA duplexes was either 100 or 200 nM, respectively. siRNA 
duplexes were transfected into cells using Dharmafect 1 (Thermo Fisher 
Scientifics, Dharmacon Products), according to manufacturer’s directions. When 
down-regulating the expression of the C11R gene, the following siRNA duplexed 
oligonulceotides were utilized (only the sense strand is shown): 5’-
CUAGAGAUAUCGACGGUAU-3’, 5’-CGGUAUUAUGCUUGUAUUA-3’, 5’- 
AGUGGUAACGCUAUCGAAA-3’), 5’-GCUAUCAGAUUAUGCGGUC-3’. Several 
known (E3L) or suspected C ORFB, F ORF A) VACV early genes were silenced 
in parallel as controls. The siRNA sequences used to down-regulate the 
expression of the C ORF B gene were: 5’-AGUCAUAACCGUAAUCCAA-3’), 5’-
ACGCUAACGGUAUCAAUAA-3’, 5’-GCAUCGUGCUUUAACAUCA-3’, 5’-
CAUAUUCGUCCCUACUAUA-3’. The siRNA sequences used to downregulate 
the expression of the F ORF A gene were: 5’-GACCUCCUACUACGUAUAA-3’, 
5’-UUUCAGAAGACUCGGCAUA-3’, 5’-GGAAUCCAAUUGUUUGAUA-3’, 5’-
AACCAACGCUCAACAGAUG-3’. For silencing of the expression of the E3L 
gene, cells were instead transfected with 50 nM of double 
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stranded synthetic oligonucleotides specific for one region of the E3L mRNA. In 
this case, the siRNA sequence used was 5’-AAUAUCGUCGGAGCUGUACAC-
3’. For all experiments involving siRNA silencing, medium was removed at 24 h 
post-transfection. Next, cells were infected with MVA (MOI = 5), and cells were 
harvested at 6 h post204 
infection.   
Regardless of whether cells were transfected or infected, cells were 
harvested and collected by using centrifugation (30 sec at 10,000 x g). 
Supernatants were removed, and cellular pellets were suspended and lysed in 
CE buffer. Clarified supernatants containing the cytoplasmic proteins were 
transferred to new centrifuge tubes, and the protein concentration of each 
sample was determined by using the BCA assay (Pierce). An equivalent amount 
of protein from each sample was loaded into separate lanes of SDS-12% 
polyacrylamide gels. Proteins were separated electrophoretically and then 
transferred to a polyvinyl difluoride membrane (PVDF; Millipore). Membranes 
were incubated in blocking buffer (Tris-buffered saline (pH7.4) containing 5% 
milk and 0.1% Tween-20) for at least one hour. Next, membranes were 
incubated at 4°C overnight in TBS-T (TBS containing 0.1% Tween-20 and 0.5% 
milk) containing one of the primary antibodies listed below, diluted in TBS-T. 
After washing membranes 3 times in TBS-T, blots were incubated with 
secondary antibody consisting of either horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (1:10,000; Fisher Scientific) or HRP-conjugated 
goat anti-mouse IgG (1:5,000; Fisher Scientific) diluted in TBS-T. The antigen-
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antibody reactions on each immunoblot were detected by using 
chemilluminescence and autoradiography. The GE Supersignal West Pic 
substrate was utilized except when blots were probed with anti-IκBα antiserum, 
according to the manufacturer’s directions. Primary antibodies included: rabbit 
anti-phospho-ERK1/2 antiserum (1:1,000; Santa Cruz Biotechnology), which 
interacts with the phosphorylated form of ERK2 and, to a lesser extent, the highly 
similar ERK1 protein; rabbit anti-ERK1/2 antiserum (1:1,000; Santa Cruz 
Biotechnology), which recognizes the ERK2 and highly similar ERK1 protein. For 
immunoblots detecting IκBα, rabbit anti-IκBα (1:5,000; Cell Signaling) was used, 
and immunoblots were re-probed with anti-actin antiserum (1:1,000). In some 
cases, a separate immunoblot was incubated with mouse monoclonal anti-E3 
antiserum, which interacts with the VACV E3 protein (Weaver et al., 2007). 
 
Detection of VACV mRNA transcripts by using reverse-transcriptase (RT)PCR.  
For experiments using pC11R to ectopically express the VGF protein, the 
expression level of C11R transcription was evaluated by using RT-PCR. To this 
end, transfected cells were lysed in RLT buffer (Qiagen), and total RNA was 
extracted using the Qiagen RNeasy kit. RT-PCR was also used to evaluate the 
extent of siRNA mediated silencing of several VACV genes: C11R, E3L, F ORFA 
and C ORF B. In this case, cells previously transfected with siRNAs and infected 
with MVA (MOI = 5) were harvested at 6 h pi, and total RNA was extracted from 
each sample using the Qiagen RNeasy kit.   
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To produce cDNA from the collected RNA, 0.5 µg of mRNA was reverse 
transcribed into single-stranded cDNA with Superscript II reverse transcriptase 
(Invitrogen) and oligo (dT) primers at 42°C for 50 min. For all PCR reactions, 1 µl 
of template cDNA was used. Amplification of C11R and GAPDH cDNA from 
transfected cells was performed in parallel by using PCR primers specific for 
each gene. Primers for C11R were 5’-ATCAGATTATGCGGTCCAGAGGGA-3’ 
and antisense oligonucleotide 5’-ACAAGCATAATACCGGGAGATGGG-3’, and 
was expected to yield a 260 bp product. Primers for GAPDH were 5’-
AAGGTCGGAGTCAACGGATTTGGT-3’ and antisense oligonucleotide 5’-
ACAAAGTGGTCGTTGAGGGCAATG-3,’ yielding a 911 bp product. Amplification 
of cDNAs from RNA from virus-infected cells were performed with the following 
oligonucleotides: primers for E3L were 5’-GCAGAGATTGTGTGTGCGGCTATT-
3’ and antisense oligonucleotide 5’-GGTGACAGGGTTAGCATCTTTCCA-3,’ and 
was expected to yield a 327 bp product (12). Primers for C ORF B were 5’-
CCTCGCTTTGTGTATCATATTCGTCCC-3’) and antisense oligonucleotide 5’-
CGGTTATGACTAAATGGTGTGCTCCG-3’ yielding a 114 bp product. Primers 
for F ORF A were 5’-GGATGCCACTGCTGGATTACATCT-3’ and reverse (5’-
TGG ATT CCA ATT CCT CCG ATG-3’ yielding a 186 bp product. For all 
experiments, GoTaq polymerase (Promega) was used for PCR. PCR conditions 
were 25 amplification rounds consisting of a denaturation step at 95°C for 45 s, 
an annealing step of 58°C (C11R, E3L, GAPDH, and C ORF B primer sets) or 
55°C (F ORF A primer sets) for 30 s, and an extension step of 72°C for 90 s. An 
additional extension step of 72°C lasted for for 5 min. A portion of each PCR 
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reaction was analyzed by 1% agarose gel electrophoresis, and amplicons were 
visualized by ethidium bromide staining. 
 
Gel electromobility shift assays (EMSAs) of nuclear-extracted proteins to detect 
NF-κB nuclear translocation.  
For this assay, cells were transfected with siRNAs targeting a specific 
VACV gene, and then infected with MVA (MOI = 5) as described above. At 6 h 
post-infection, cells were collected by scraping and the method for isolating 
nuclear proteins from virus-infected cells was described previously (Gedey et al., 
2006).  The concentration of nuclear protein in each sample was determined by 
using the BCA Protein Assay Kit (Pierce). Five µg of each extract was incubated 
with 0.35 pmol of 32P labeled double-stranded oligonucleotides containing 
binding sites for the NF-κB transcription factor in Gel Shift Assay System Binding 
buffer (Promega) as per manufacturer’s directions. Some reactions also included 
excess molar amounts of non-radiolabeled oligonucleotides that either contained 
NF-κB binding sites or lacked NF-κB binding sites, such as the AP-1 
oligonucleotide, or 1 µg monoclonal anti-p65 antiserum (Santa Cruz 
Biotechnology). Following incubation, reactions were resolved electrophoretically 
in a 6% acrylamide gel (Invitrogen) under non-denaturing conditions. Afterward, 
the gels were dried onto filter paper, exposed to a phosphorimager plate 
(Molecular Devices), and images were developed and analyzed using the 
ImageGauge and ImageReader programs, respectively (Fuji). 
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Results 
MVA-induced NF-κB and ERK2 activation is triggered by the EGFR.  
MVA infection activates NF-κB in the human 293T fibroblast cell line and 
in other primary and transformed fibroblast cells of human or murine origin 
(Delaloye et al., 2009, Gedey et al., 2006, Lynch et al 2009, Martin and Shisler 
2009). Previously, we showed that ERK2 activation occurs prior to, and is 
necessary for, MVA-induced NF-κB activation in 293T cells (Gedey et al., 2006, 
Martin and Shisler 2009). However, the upstream proteins responsible for MVA-
induced ERK2 activation were unknown. To identify these, we asked whether the 
inhibition of signal transduction pathways known to activate ERK2 also prevented 
MVA-induced NF-κB activation.   
One such pathway involves EGFR; the auto-phosphorylation of the 
cytoplasmic tail of the EGFR results in the downstream activation of the ERK1 
and ERK2 proteins (Prenzel et al., 2001). It is also known that EGFR activation 
and ERK1/2 activation can each stimulate NF-κB (Habib et al., 2001, Pearson et 
al., 2001, Sethi et al., 2007). Thus, our working hypothesis was that EGFR 
activated NF-κB via ERK2 activation. While the EGFR is present on the surface 
of 293T cells, it is absent from the surface of CHO K1 cells (Bringman et al., 
1987, and Jo et al., 2003). However, both cell lines permit poxviral uptake and 
early gene expression during infection (Franke et al., 1985, Lynch et al., 2009). 
To probe the role of EGFR in MVA-induced NF-κB activation, CHO K1 cells were 
infected with MVA and NF-κB activity was examined, using an NF-κB-dependent 
luciferase reporter assay to evaluate NF-κB activation (Figure 3.1A). As 
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previously reported (Martin and Shisler 2009, Oie and Pickup 2001), MVA 
infection of 293T cells activated NF-κB, as indicated by the increased levels of 
luciferase activity in comparison to luciferase activity from mock-infected 293T 
cells. In contrast, luciferase activity remained low in mock- or MVA-infected CHO 
K1 cells, suggesting that the EGFR was necessary for MVA-induced NF-κB 
activation.  
ERK2 activation precedes and is required for MVA-induced NF-κB 
activation in 293T cells (Gedey et al., 2006).  As shown in Figure 3.1B, MVA-
induced ERK2 activation is detected by the presence of the phosphorylated form 
of the 42-kDa ERK2 protein. The anti-phospho-ERK2 antibody also cross-reacts 
with the highly similar phospho-ERK1 protein, as is evidenced by the presence of 
a higher molecular weight, 44 kDa, band in most samples. In contrast, mock-
infected 293T cells have no detectable activated ERK2 or ERK1. MVA infection 
of CHO K1 cells did not visibly increase ERK2 activation; the densities of the 
phospho-ERK2 bands remained similar in mock- versus MVA-infected cells. 
These data suggest that the EGFR is also required to activate ERK2 during MVA 
infection.   
It was shown previously that the presence of AG1478 (Gedey et al., 
2006), a compound that selectively inhibits EGFR auto-phosphorylation (Daub et 
al., 1996), reduces MVA-induced NF-κB activation. Figure 3.2A shows a similar 
observation: when 293T cells were treated with AG1478, MVA-induced luciferase 
activity was diminished. AG1478 also decreased MVA-induced ERK2 activation 
in 293T cells; the intensity of the 42-kDa phospho-ERK2-containing band was 
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visibly reduced when infections proceeded in the presence versus the absence of 
AG1478 (Figure 3.2B). Unmodified ERK1 and ERK2 protein levels were detected 
in similar amounts in MVA-infected cells, regardless of the presence or absence 
of drug, indicating that AG1478 did not cause its effects by decreasing ERK2 
protein levels. 
 
The Raf and Ras proteins, but not NIK, are dispensable for MVA-induced ERK2 
and NF-κB activation. 
It is well known that EGFR phosphorylation activates Ras GTPase, which 
in turn binds to and phosphorylates Raf (Prenzel et al., 2001). Raf then 
phosphorylates MEK proteins, the upstream kinases that activate ERK1/2 
proteins (Prenzel et al., 2001). To evaluate the requirement of the Ras and Raf 
proteins in MVA activation of NF-κB, dominant negative (DN) forms of Raf or 
Ras, which were previously shown to inhibit ERK1/2 activation (Fiordalisi, et al., 
2002, Sutor et al., 1999), were over-expressed in 293T cells. Next, cells were 
infected with MVA, and NF-κB controlled luciferase activity was measured. As 
shown in Figure 3.3A, MVA infection of pcDNA3.1-transfected cells activated NF-
κB about 22-fold as compared to mock-infected cells. MVA retained its ability to 
activate NF-κB in cells transfected with pRasDN, suggesting that Ras was 
dispensable for MVA-induced ERK2 activation. The over-expression of DN Raf 
itself activated NF-κB since luciferase activity levels were 45-fold higher in mock-
infected cells transfected with pRafDN versus pcDNA3.1. Regardless, luciferase 
activity increased further when cells were infected with MVA, indicating that Raf 
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was not required for NF-κB activation. Several reports show that the EGFR 
activates NF-κB via NIK (Habib et al., 2001). In contrast to Ras and Raf, NIK 
appeared to be important for MVA-induced NF-κB activation because NF-κB 
remained inactive in cells over-expressing DN NIK (Figure 3.3A).  
Based on data from Figure 3.3A, it is hypothesized that MVA-induced 
ERK2 activation will still occur in cells expressing DN Ras, or DN Raf, but not in 
cells expressing DN NIK. As shown in Figure 3.3B, the intensity of the phospho-
ERK2-containing bands are more intense in cells infected with MVA versus 
mock-infected, regardless of the presence of DN Raf, DN Ras or DN NIK. These 
data suggest that MVA-induced ERK2 activation was independent of each of 
these three proteins. 
 
Silencing of the C11R gene reduces ERK2 and NF-κB activation. 
The C11R gene of orthopoxviruses encodes VGF, a soluble, secreted viral 
homolog of epidermal growth factor (EGF) (Brown et al., 1985, Twardzik et al., 
1985, Twardzik et al., 1987). VGF binds to the extracellular domain of the EGFR, 
resulting in EGFR activation (Tzahar et al., 1998). To test if the C11R gene was 
responsible for MVA-induced NF-κB activation, we infected cells with MVA under 
conditions in which the C11R gene was transcriptionally silenced. NF-κB 
activation was evaluated by using gel mobility shift assays (EMSAs) instead of 
luciferase assays to avoid technical difficulties encountered when cells are 
transfected sequentially with luciferase reporter plasmids and siRNAs prior to 
infections. For EMSAs, if nuclear extracted proteins shift the mobility of 
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radiolabeled oligonucleotides that possess NF-κB binding sequences, then NF-
κB is considered to be present in the nucleus and activated (Gedey et al., 2006). 
As shown in Figure 3.4A (lanes 4 and 5), the intensity of an NF-κB-containing 
band (*) was greater in nuclear extracts from MVA- versus mock-infected cells, 
indicating that MVA infection activated NF-κB. The mobility of this band was 
super-shifted (+) when anti-NF-κB antibody (p65 Ab) was present in reactions 
(Figure 3.4A, lane 3), proving that NF-κB was indeed present in the complex. 
The band disappeared when an excess of unlabeled oligonucleotides containing 
NF-κB binding sites (Figure 3.4A, lane 2), but not AP-1 binding sites (Figure 
3.4A, lane 1), was present in the reaction, showing that the interaction between 
NF-κB and its target oligonucleotide was specific. The C11R gene was partially 
responsible for MVA-induced NF-κB activation because the intensity of the NF-
κB containing band was reduced when C11R was silenced (Figure 3.4A, lane 7), 
but not when E3L was silenced (Figure 3.4A, lane 6), or in the absence of siRNA 
oligonucleotides (Figure 3.4A, lane 5).   
The effectiveness of the siRNA silencing of C11R was assayed by RT-
PCR (Figure 3.4B). The intensities of the C11R or E3L-containing amplicons 
were greatly reduced when cells were transfected with C11R or E3L siRNA 
versus mock-transfected. siRNA  silencing of E3L did not affect the transcription 
of the poxvirus C11R gene (data not shown), indicating that the siRNA silencing 
of a viral gene was specific. GAPDH mRNA  levels remained similar (Figure 
3.4B), illustrating that the decrease in C11R or E3L gene expression did not 
result in a general decrease in transcription.   
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When cells were transfected with siRNAs directed against C11R, MVA-
induced phospho-ERK2 levels also were greatly reduced as compared to mock-
transfected cells (Figure 3.4C). In this case, phospho-ERK1 proteins were no 
longer detected because a lesser amount of protein from each sample (7 µg) was 
used for immunoblotting as compared to other experiments. This effect was 
specific for the silencing of the C11R gene because MVA still activated ERK2 
when cells were transfected with siRNAs specific for two other predicted MVA 
genes (F ORF A, C ORF B)(McCraith et al., 2000). As would be expected, 
unmodified ERK1 and ERK2 protein levels remained similar in cells regardless of 
infection state, or the presence or absence of transfected siRNAs. As shown in 
Figure 3.4D, the transfection of siRNAs specific for either C11R, C ORF B or F 
ORF A greatly reduced the production of the mRNAs for those genes, but not for 
GAPDH. 
 
Deletion of the C11R gene from MVA reduces ERK2 and NF-κB activation. 
To continue to test the hypothesis that the C11R gene product was 
responsible for MVA-induced NF-κB activation, we created a mutant MVA virus 
lacking the C11R gene (MVAΔC11R). While deletion of C11R from a wild-type 
VACV results in a mutant virus that possesses a smaller plaque phenotype and a 
diminished replication efficiency (Buller et al., 1988a, Buller et al, 1988b), 
MVAΔC11R and MVA foci were similar in size and replicated to similar titers in 
CEF monolayers (data not shown).  
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The NF-κB activation states of cells infected with MVA versus MVAΔC11R 
were compared (Figure 3.5). NF-κB-controlled luciferase activity was decreased 
in MVAΔC11R-infected cells by 30% as compared to MVA-infected cells (Figure 
3.5A), suggesting that the C11R gene product does indeed contribute to MVA-
induced NF-κB activation. IκBα protein levels were assessed as a second 
measure of NF-κB activation. IκBα binds to NF-κB to inhibit the nuclear 
translocation of NF-κB (Baeuerle and Baltimore 1988). Thus, the presence of 
IκBα in mock-infected cells indicates inert NF-κB (Figure 3.5B). As compared to 
mock-infected cells, the intensity of the IκBα-containing band was reduced in 
MVA-infected cells, indicating that NF-κB was activated. The intensity of the 
IκBα- containing protein band was higher in MVAΔC11R-infected cells as 
compared to MVA-infected cells, suggesting that the C11R gene activated NF-
κB. Actin levels remained similar in all cell samples.   
Since ERK2 activation is required for MVA-induced NF-κB activation 
(Gedey et al., 2006), phospho-ERK2 levels were expected to be diminished in 
cells infected with MVAΔC11R. As shown in Figure 3.5C, phosphorylated ERK2 
levels were decreased in MVAΔC11R- versus MVA-infected cells. Unmodified 
ERK1/2 proteins remained constant in mock- or virus-infected cells, ruling out the 
possibility that a decrease in ERK2 activation was due to decreased ERK2 
protein levels. The early E3 VACV protein levels were similar in MVA- and 
MVAΔC11R-infected cells, illustrating that the expression of other early VACV 
genes occurred in 293T cells despite the absence of the C11R gene. 
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Ectopic expression of the C11R gene is sufficient to activate NF-κB. 
To test if the C11R product induced NF-κB activation independent of virus 
infection, 293T cells were transfected with a plasmid encoding the C11R gene, 
and NF-κB activation was assessed by using a NF-κB-dependent luciferase 
reporter assay. As shown in Figure 3.6A, luciferase activity was 14-fold higher in 
cells transfected with pC11R versus a plasmid lacking C11R (pcDNA3.1). 
Unfortunately, antibodies against the orthologous variola virus C11 product 
(SPGF)(Kim et al., 2004) did not detect the VGF in cellular extracts or 
concentrated supernatants (data not shown). The expression of the C11R gene 
was evaluated by using RT-PCR (Figure 3.6B). Following reverse transcription of 
total RNA from pcDNA3.1- or pC11R-transfected cells, the resultant C11R cDNA 
was amplified by using PCR with primers specific for the C11R gene. As shown 
in Figure 3.6B, the C11R-containing amplicon was visible when using genetic 
material from pC11R transfected cells, but not vector-transfected cells. 
Amplicons containing GAPDH cDNA were detected in similar amounts from both 
samples. 
 
The C11R gene is partially responsible for MVA-induced NF-κB activation in 
Hacat, but not THP-1, cell lines. 
MVA infection of THP-1 cells activates NF-κB via the toll-like receptor 2 
(TLR2)-TLR6-MyD88 pathway (Delaloye et al., 2009). In contrast, MVA infection 
of 293T cells activates NF-κB via a MyD88-independent pathway (Martin and 
Shisler 2009). These data suggest that MVA may use different receptors in cells 
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of different origin to trigger NF-κB activation. To test this hypothesis, we 
examined the effect of MVAΔC11R infection on NF-κB in monocytic THP-1 and 
transformed keratinocyte Hacat cells. These two cell lines were specifically 
studied because these two cells are infected soon after inoculation with the 
smallpox vaccine (Liu et al., 2010, Yu et al., 2009). NF-κB activation was 
evaluated indirectly, by detecting the decrease of IκBα protein levels in infected 
cells.   
As shown in Figure 3.7A, the intensities of the IκBα bands are similar in 
mock- or WR-infected THP-1 cells, indicating that NF-κB is inactive. The intensity 
of this band decreased when cells were infected with MVA, supporting the 
previous finding that MVA infection of THP-1 cells activates NF-κB (Delaloye et 
al., 2009). MVAΔC11R infection did not greatly alter IκBα protein levels, 
indicating that MVA-induced NF-κB activation is independent of the C11R gene. 
Actin levels were similar in each sample, ruling out the possibility that alterations 
in IκBα protein levels was due to differences in the amounts of proteins present 
in each well of the gel.  
Identical infections were also performed using Hacat cells (Figure 3.7B). 
The intensity of the IκBα band was decreased when cells were infected with MVA 
versus mock-infected, indicating that MVA infection activated NF-κB. IκBα levels 
were higher in MVAΔC11R- versus MVA-infected cells, suggesting that the C11R 
gene product stimulated NF-κB. IκBα was detected in lysates from WR-infected 
Hacat cells, indicating that NF-κB remained inactive in these infected cells. 
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Discussion 
MVA is an attenuated VACV lacking many immune evasion genes, 
including several genes encoding NF-κB inhibitory proteins that are otherwise 
present in its parental genome (Antoine et al., 1998). As a result, MVA activates 
NF-κB in a variety of cell types (Delaloye et al., 2009, Lynch et al., 2009, Oie and 
Pickup 2001, Willis et al., 2009). For 293T cells, virus entry and early gene 
expression are required for NF-κB activation (Martin and Shisler 2009). The 
purpose of this study was to identify cellular and viral factors responsible for 
MVA-induced NF-κB activation. Here, we find that the expression of the early 
C11R gene plays a role in NF-κB activation in 293T and Hacat cells; MVA 
viruses devoid of the C11R gene have a reduced ability to activate NF-κB. 
Moreover, ectopic expression of the C11R gene also activated NF-κB. Since the 
C11R gene encodes VGF, the current model is that extracellular VGF binding to 
the EGFR results in EGFR activation, triggering ERK2 activation and NF-κB 
activation. In support of this theory, we show that chemical inhibition or absence 
of the EGFR results in diminished or loss of NF-κB activation in response to MVA 
infection.  
Wild-type VACV activates EGFR via extracellular interactions to stimulate 
macropinocytosis of VACV (Mercer et al., 2010). The VGF protein binds to EGFR 
to suppress apoptosis in infected host cells (Postigo et al., 2009), stimulate the 
expression of the mitogenic egr-1 gene in host cells (Andrade et al., 2004), and 
induce proliferation in uninfected cells (Buller et al., 1988b). This report describes 
a fourth outcome of VGF-EGFR activation, stimulating NF-κB during MVA 
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infection. Unlike the other effects of VGF-EGFR interactions, NF-κB activation 
could present deleterious effects during virus infection: stimulating the 
transcription of myriad immune molecules with anti-viral functions (Guerra et al., 
2004). We hypothesize that VGF binds to the EGFR to induce “pro-viral” events 
despite the fact that such interactions also activate NF-κB. To counteract this 
undesired activity then, wild-type VACV expresses immune evasion proteins, 
such as B14 and K1 (Chen et al., 2008, Shisler and Jin 2004), to specifically 
disarm EGFR-induced NF-κB activation while permitting pro-viral events. This 
exemplifies a sophisticated approach poxviruses employ to differentially 
manipulate EGFR-triggered events for their benefit.  Proper EGFR signal 
transduction is critical for entry of several virus types into cells (Eierhoff et al., 
2010, Melnick et al., 2009), and aberrant EGFR expression or signaling is 
associated with certain types of cancers (Navolanic et al., 2003). Thus, 
identifying how VACV modulates EGFR-mediated signal transduction pathways 
will likely yield new approaches and targets for anti-viral or anti-cancer therapies.  
Activation of the EGFR stimulates myriad signaling pathways that trigger 
cellular proliferation, survival and cell cycle progression (Prenzel et al., 2001). 
For example, phosphorylated EGFR triggers Sos, stimulating the Ras-Raf-
MEK1/2-ERK1/2 pathway to result in cellular proliferation (Fan and Goff 2000). 
EGFR also stimulates other signaling molecules, including PI3K and Ral (Prenzel 
et al., 2001). Data here show that EGFR-induced NF-κB activation is distinct 
from this pathway since DN Ras and Raf proteins permitted MVA-induced NF-κB 
and ERK2 activation. NIK was required for MVA-induced NF-κB activation, in 
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agreement with another report showing that EGFR stimulates NF-κB via NIK 
(Habib et al., 2001). However, NIK was not responsible for MVA-induced ERK2 
activation, suggesting that other NF-κB activation pathways may be triggered in 
MVA-infected cells. In support of this, it was observed that the presence of 
AG1478 during MVA infection or MVAΔC11R infection of 293T cells did not 
completely abolish NF-κB activation. It is also known that MVA infection activates 
PKR, a protein also known to stimulate NF-κB (Gil et al., 2000, Gil et al., 2004, 
Lynch et al., 2009, Willis et al., 2009).  
Infection of Hacat, 293T and THP-1 cells with MVAΔC11R resulted in 
different IκBα degradation patterns, implying that C11R was responsible for NF-
κB activation in Hacat and 293T cells, but not in THP-1 cells. This finding agrees 
with past data showing that MVA uses different signal transduction patterns to 
stimulate NF-κB in a cell-type dependent manner. For example, it is known that 
NF-κB activation is MyD88-dependent in THP-1 cells (Delaloye et al., 2009) and 
MyD88-independent in 293T cells (Martin and Shisler 2009). Moreover, NF-κB 
activation only requires virus binding to THP-1 cells (Delaloye et al., 2009), but 
requires synthesis of early viral genes in 293T cells (Martin and Shisler 2009). 
These data exemplify the complexity of virus infection in vivo, in which cells of 
different origins may respond to virus infection in unique manners. Thus, the 
successful neutralization of viral infections may require the simultaneous 
presence of small molecules that target myriad signal transduction pathways.  
MVA was used safely as a smallpox vaccine in Germany in the 1970s 
(Hochstein-Mintzel et al., 1972), and is now a promising vaccine vector for use 
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against human and veterinary diseases (Jacobs et al., 2009).  One shortcoming 
of the current MVA vector is it relatively low immunogenicity as compared to its 
parental VACV. Thus, many MVA-based vaccine protocols use multiple 
inoculations to generate a robust antibody response. NF-κB controls the 
important process of inflammation and cell survival (Ghosh et al., 1998), making 
it a prime candidate for controlling viral immunogenicity. Yet, it is unclear how 
altering NF-κB affects the immunogenicity of MVA. One hypothesis is that 
activated NF-κB decreases the immunogenicity of MVA: NF-κB would stimulate 
the expression of intrinsic or extracellular anti-viral immune response proteins to 
lyse cells or to attract cytotoxic effector cells to an area of infection. The lysis of 
virus-infected cells would eliminate virus infection before an appropriate acquired 
immune response would develop. A competing hypothesis is that NF-κB 
activation would enhance MVA’s immunogenicity; NF-κB would stimulate the 
synthesis of pro-survival genes in infected cells, which would allow host cells to 
survive longer. In this case, infected host cells would give prolonged signals to 
stimulate the immune response to increase immunogenicity. An MVA that no 
longer activates NF-κB is required to test the above models. Here, we identify 
that the MVAΔC11R is one such virus, in that it has a diminished ability to 
activate NF-κB in keratinocytes. How this virus affects early events in virus-host 
interactions will help solve the question of the role of NF-κB activation in viral 
immunogenicity. 
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Figure 3.1. MVA does not activate NF-!B in cells lacking the EGFR.  
(A)Subconfluent monolayers of 293T or CHO-K1 cells were transfected with 
pNF-κBluc and pRL-null. At 24 h later, cells were either mock-infected or infected 
with MVA (MOI=10). Cells were lysed in PLB at 6 h pi, and the ratio of firefly to 
sea pansy luciferase activities were normalized to that of their corresponding 
mock infected cells, whose value was set to 1. An asterisk is indicative of 
statistical significance (p < 0.05). (B) 293T or CHO K1 cells were either mock-
infected or infected with MVA (MOI=10). At 4 h pi, cells were harvested and lysed 
in CE buffer. 15 µg of each prepared cytoplasmic extract were electrophoretically 
separated in SDS-12% polyacrylamide gels, and transferred to PVDF mem 
branes. Membranes were incubated with antibodies recognizing the phosphory 
lated form of ERK1 and ERK 2 (p-ERK1/2), and then re-probed with antibodies 
recognizing the unmodified forms of ERK1 and ERK2. 
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Figure 3.2. The AG1478 drug reduces ERK2 and NF-κB activation in MVA-
infected cells. (A) Subconfluent 293T cellular monolayers were transfected with 
plasmids pNF-κBluc and pRL-null. At 24 h post-transfection, cells were either 
mock-infected or infected with MVA (MOI=10) in DMSO-containing medium in 
which AG1478 (50 µM) was present or absent for 30 min prior to and throughout 
infection. At 6 h pi, cells were lysed in PLB, and luciferase activities were 
measured. The ratio of firefly to sea pansy luciferase activities was normalized to 
that of mock-infected cells, whose value was set to 1. An asterisk is indicative of 
statistical significance (p < 0.05). (B) 293T cellular monolayers were pretreated 
with DMSO-containing medium either lacking or containing AG1478 (50 µM) for 
30 min prior to infection. The respective compounds remained present in medium 
for the duration of infection. Cells were mock-infected or infected with MVA 
(MOI=10). Cells were harvested at 4 h pi, and 20 µg of each of the prepared 
cytoplasmic extracts were separated by SDS-12%PAGE and transferred to 
PVDF membranes. Membranes were analyzed for the activated (phosphorylated) 
forms of the ERK1 and ERK2 proteins via immunoblotting (top panel). Blots were 
re-probed with antibodies recognizing the unmodified ERK1 and ERK2 proteins. 
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Figure 3.3. The effect of DN Ras, Raf or NIK on MVA-induced NF-!B or ERK2 
activation. (A) 293T cells were co-transfected with pNF-!Bluc and pRL-null and 
either pcDNA3.1, pRafDN, pRasDN or pNIKDN. At 24 h post-transfection, cells 
were either mock-infected or infected with MVA (MOI=10). Cells were harvested 
at 6 h pi and evaluated for luciferase activities. The ratios of firefly to sea pansy 
luciferase activities for each sample were normalized to that of mock-infected 
cells, whose value was set to 1. (B) 293T cells were transfected with 1000 ng of 
pcDNA3.1, pRafDN, pRasDN or pNIKDN. At 24 h later, cells were either mock-
infected or infected with MVA (MOI=10). At 4 h pi, cells were harvested and 
lysed, and 15 µg of each of the cellular lysates were analyzed by immunoblotting 
with antibodies against phosphorylated ERK1/2 (p-ERK1/2) and then developed  
by using chemilluminescence. The blot was re-probed with antibodies against 
ERK1/2 and developed by using chemilluminescence. 
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Figure 3.4. siRNA silencing of the C11R gene diminishes MVA-induced 
ERK2 and NF-κB activation. Subconfluent 293T cellular monolayers were 
transfected with chemically synthesized siRNAs against the indicated VACV 
genes or mock-transfected. 100 nM siRNA was used for transfection when 
silencing the C11R, C ORF B or F ORF A genes. 50 nM siRNA was used for 
transfection to silence E3L gene expression. At 24 h later, cells were mock-
infected or infected with MVA (MOI = 5), and infected cells were harvested 6 h 
later. Cells were harvested and (A) nuclear or (C) cytoplasmic proteins were 
extracted. (B and D) Total RNA was isolated from an identical set of cells that 
were transfected and infected in parallel. (A) Nuclear extracts from infected cells 
were incubated with [32P] ATP labeled oligonucleotides containing a consensus 
NF-!B binding site. In some reactions, non-radiolabeled oligonucleotides 
containing either NF-κB binding sites (NF-κB) or AP-1 binding sites (AP-1) were  
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Figure 3.4 (cont.) 
included. Antibody against the p65 subunit of NF-κB was also included where 
indicated (p65 Ab). The reaction mixture was analyzed by electrophoresis in a 
6% gel, under non-denaturing conditions. An asterisk (*) indicates NF-κB bound 
probe. (B) From the RNA isolated from an identical set of cells, mRNA was 
reverse transcribed into cDNA.  C11R, E3L and GAPDH cDNAs were PCR 
amplified, and a portion of each reaction was analyzed by electrophoresis in a 
1% agarose gel.  Ethidium bromide was used to visualize the presence of PCR 
amplicons. (C) Prepared cytoplasmic extracts were analyzed by immunoblotting, 
probing the blots with antibodies against the phosphorylated form of ERK1/2 (p-
ERK1/2).  The blot was then re-probed with antiserum against ERK1/2.  (D) From 
the RNA isolated from an identical set of cells, mRNA was reverse transcribed 
into cDNA.  C11R, C ORF B, F ORF A or GAPDH cDNAs were amplified by 
using PCR.  A portion of each PCR reaction was analyzed by electrophoresis in 
a 1% agarose gel and visualized with ethidium bromide. 
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Figure 3.5. An MVA virus lacking C11R (MVAΔC11R) reduces ERK2 and NF-
κB activation (.A) 293T cells were transfected with luciferase reporter plasmids 
(pNF-!Bluc and pRL-null) 24 h before infection. Cells were either mock-infected 
or infected with the indicated viruses (MOI=5). At 6 h pi, cells were lysed, and 
firefly and sea pansy luciferase activities were measured. The ratio of firefly to 
sea pansy luciferase activities were normalized to that of mock-infected cells, 
whose value was set to 1. An asterisk is indicative of statistical significance (p < 
0.05). (B, C) 293T cells were either mock-infected or infected with either MVA or 
MVA"C11R (MOI = 10). At 4 h pi, cells were lysed, and (B) 10 µg of prepared 
cytoplasmic extracts were analyzed via immunoblotting, using antibodies 
recognizing IκBα. The blot was re-probed with antiserum against actin. (C) 20 µg 
of cytoplasmic extracts from each sample were analyzed by immunoblotting, 
using antibodies recognizing the phosphorylated form of ERK2 (p-ERK1/2). The 
blot was re-probed with antibodies recognizing ERK1/2. A duplicate blot was 
probed with antiserum against the viral E3 protein. 
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Figure 3.6. Ectopic expression of C11R induces NF-κB activation. 
Subconfluent 293T cellular monolayers were co-transfected with pNF-κBluc, 
pRL-null and either pcDNA3.1 or pC11R. At 24 h post-transfection, cells were 
lysed in (A) PLB and luciferase activities were measured, or (B) lysed and total 
RNA was isolated from cellular lysates. For the former conditions, the ratios of 
firefly to sea pansy luciferase activities were normalized to that of mock-infected 
cells, whose value was set to 1. An asterisk is indicative of statistical significance 
(p < 0.05). When using total RNA isolated from transfected cells, 0.5 µg of total 
RNA per sample was reverse transcribed using oligo d(T) as a primer to 
generate cDNA. Then, primers specific for either C11R or GAPDH were used in 
subsequent PCR reactions. A portion of each PCR reaction was analyzed by 
electrophoresis in a 1% agarose gel, and amplicons were visualized by ethidium 
bromide stain. 
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Figure 3.7. C11R contributes to MVA-induced IκBα degradation in human 
keratinocytes. (A) THP-1 cells were incubated in medium containing PMA (100 
ng/ml) for 18 h. Cells were mock-infected or infected with MVA, MVAΔC11R, or 
WR (MOI=5). Cells were collected and lysed at 6 h pi. 10 µg of prepared cyto 
plasmic extracts from each sample were analyzed via immunoblotting with 
antibodies against IκBα. Blots subsequently were reprobed with antibodies 
against actin. (B) Hacat cells were either mock-infected or infected with MVA, 
MVAΔC11R, or WR (MOI=10). At 6 h later, cells were lysed, and 10 µg of 
prepared cytoplasmic extracts from each sample were analyzed via 
immunoblotting with antibodies against IκBα. Blots subsequently were reprobed 
with antibodies against actin. 
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Chapter IV: Multiple Viral Proteins Expressed Early in an 
Infection Affect MVA-Induced ERK1/2 and NF-κB 
Activation 
 
Introduction 
Nuclear factor-κB is a highly conserved eukaryotic proinflammatory 
transcription factor (Oeckinghaus and Ghosh 2009).  As a consequence, viruses 
employ a number of methods to evade and manipulate the NF-κB pathway, 
which enhances their immune evasion. Some viruses such as adenovirus and 
poliovirus (Hiscott, et al. 2006) encode proteins that inhibit the activation of NF-
κB.  Interestingly, other viruses express proteins that activate NF-κB, such as the 
herpesviruses Epstein-Barr virus and human cytomegalovirus (Hiscott, et al. 
2006).  The modulation of the NF-κB pathway can be quite complicated as some 
viruses encode both inhibitory and activating proteins for NF-κB.  The poxvirus 
Vaccinia Virus (VACV) is one such virus, which serves as the vaccine for Variola 
Virus, the causative agent of smallpox. Wild type VACV encodes a number of 
genes whose products inhibit NF-κB, including A46L (Gonzalez and Esteban 
2010), an inhibitor of TLR signaling, and M2L, which inhibits the ERK1/2 pathway 
(Hinthong, et al. 2008).  We have also shown that VACV also encodes proteins 
capable of inducing NF-κB (Martin and Shisler 2009).  While expression of these 
proteins does not result in the activation of NF-κB during an infection of the wild 
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type virus, NF-κB is activated during infection with the attenuated strain Modified 
Vaccinia Virus Ankara (MVA). Because MVA can no longer replicate in human 
cells, it is considered safer than wild type VACV, making it a more attractive 
vaccine and vaccine vector alternative.  Previously, we showed that early viral 
protein expression was the stage of the MVA lifecycle responsible for activating 
NF-κB in the 293T fibroblast cell line (Martin and Shisler 2009).  Specifically, we 
identified that the viral gene, C11R, contributed to the activation of NF-κB and 
ERK1/2 during an MVA infection (in submission).  However, even when C11R 
was deleted from MVA (MVAΔC11R), NF-κB activation, while decreased, was 
still observed.  
Consequently, we decided to search for other viral genes that could 
contribute to the observed NF-κB activation.  Candidate early viral genes 
responsible for this phenotype were identified based on their ability to activate 
NF-κB when expressed independently of infection.  Twenty-five additional ORFs 
were identified that were expressed either early or at an undetermined time 
during infection, including E7R and A35R.  siRNA downregulation of candidate 
viral ORFs was utilized to assess the necessity of a viral ORF expression for 
MVA-induced NF-κB activation.  Using this approach, when the expression of 
either the E7R or A35R ORFs was dampened, the NF-κB and ERK2-activating 
phenotype of MVA in 293T cells was diminished, similar to the effects seen with 
C11R silencing (in submission).  Thus, it appears that MVA utilizes multiple 
proteins to induce NF-κB activation in fibroblast cells. 
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Materials and Methods 
Cells, viruses and plasmids.   
The human kidney fibroblast HEK293T (293T), baby hamster kidney 
(BHK-21).  All cells were cultivated in Eagle’s minimal essential medium (EMEM) 
supplemented with 10% fetal calf serum (FCS; Hyclone), referred to as complete 
medium.   MVA, an attenuated strain of vaccinia virus (Mayr et al., 1975), and 
MVAΔA35R (gift from Rachel Roper) was amplified in primary CEF cells (Charles 
Rivers Laboratories).    
A plasmid library, in which known and predicted individual ORFs from 
vaccinia virus are present in a eukaryotic expression vector, was previously 
described (Tscharke et al., 2006).  An siRNA library, which contains four siRNAs 
per vaccinia gene target, was provided by the Dharmacon (ThermoFischer). 
Each siRNA sequence was designed to recognize a unique viral nucleotide 
mRNA sequence present in the vaccinia ORF of interest.  Moreover, each viral 
siRNA sequence was compared to human and vaccinia genomes, using BLAST; 
ds RNA molecules were not generated if the siRNA sequence was predicted to 
potentially bind to human or undesired portions of viral RNA.  Thus, the 
possibility of off-target effects of these RNA molecules was minimized. The 
sequences of the ds RNA molecules, and the concentrations used for silencing 
the expression of an individual ORF, are listed below. 
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siRNA silencing of viral ORFs.   
Transcriptional silencing experiments proceeded as follows.  For 
experiments in which cells were transfected with siRNA to silence the expression 
of a viral gene, subconfluent monolayers of 293T cells were plated into 24-well 
plates.  At 24 h later, cells were transfected with a solution containing siRNA 
molecules specific for 4 different regions of a viral mRNA (listed in the paragraph 
that follows). The final concentration of each siRNA in cellular medium was either 
25 or 50 nM (as indicated in the figure legends), such that the total final 
concentration of siRNA duplexes was either 100 or 200 nM. siRNA duplexes 
were transfected with Dharmafect 1 (Thermo Fisher Scientifics, Dharmacon 
Products), according to manufacturer’s directions.  At 24 h post-transfection, 
medium was removed, cells were infected with MVA (multiplicity of infection; MOI 
= 5) for 1 hour, and cells were harvested 6 h post-infection. Cytoplasmic and 
nuclear proteins or total RNA were extracted as described below. 
When downregulating the expression of the C11R ORF, the following 
siRNA duplexed oligonulceotides were utilized (only the sense strand is shown): 
C11-A (5’-CUA GAG AUA UCG ACG GUA U-3’), C11-B (5’-CGG UAU UAU 
GCU UGU AUU A-3’), C11-C (5’-AGU GGU AAC GCU AUC GAA A-3’), C11-D 
(5’-GCU AUC AGA UUA UGC GGU C-3’).  For downregulating of the E7R ORF, 
the following siRNA molecules were used: E7-A (5’-CAA UGU AAC GCG UCU 
GUU U-3’), E7-B (5’-GUA UAU UAG UGA CGA AUC A-3’), E7-C (5’-GAA CAA 
CUC UCU ACC CUA A-3’), E7-D (5’-UAA CAG AUA CGA AGA CUA U-3’).  For 
downregulating the expression of the A35R ORF, the following siRNA duplexes 
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were used: A35-A (5’-GAU GGG AAA UGC AAU AGU A-3’), A35-B (5’-GGC 
AAU GGA UGG AUC AUA A-3’), A35-C (5’-GGA CCA UAC AUU AUA GGU A-
3’), A35-D (5’-AAA UAG AUG UAC GGG AUA U-3’).  These four oligonucleotide 
complexes were used to downregulate J2R: J2-A (5’-CGA GUU AGA CGU UAU 
CAA A-3’), J2-B (5’-GAC UAU GGA CGC AUG AUA A-3’), J2-C (5’-GCG GAC 
AUA UUC AGU UGA U-3’), J2-D (5’-UAU AGU AGC CGC ACU CGA U-3’). The 
following four oligonucleotide complexes were used to downregulate H5R: H5-A 
(5’-CUG UAG AGC UCG AUG AUA G-3’), H5-B (5’-CGA CGG UUC UAG AGG 
AUG U-3’), H5-C (5’-AAA GGU GGC UAC CGA CAA U-3’), H5-D (5’-UUA CAA 
CAC UAU CUG AUC U-3’).  The following four oligonucleotide complexes were 
used to downregulate A ORF L: AL-A (5’-GGC GGU UC GGU ACA UAU A-3’), 
AL-B (5’-CGU CUG AGA UGG AAA UGU U-3’), AL-C (5’-AGG CAU CGA UCG 
UAG CU A-3’), AL-D (5’-AAU ACG GAG UCU UCG AUA A-3’).  For silencing of 
the expression of the E3L ORF, cells were instead transfected with 50 nM of 
double-stranded synthetic oligonucleotides specific for one region of the E3L 
mRNA.  The siRNA sequence used was (5’-AAU AUC GUC GGA GCU GUA 
CAC-3’)(Dave et al., 2006).   
An additional transcriptional silencing experiment involved A35R 
downregulation by using an siRNA Expression Cassette (SEC), purchased from 
Ambion.  The SEC contains a hairpin siRNA template between a human H1 
promoter and a termination sequence for RNA polymerase.  Transfection of the 
siRNA expression cassette results in the expression of functional siRNAs.  The 
SEC was generated via PCR per manufacturer’s instructions for the Silencer® 
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Express Kit.  The primer sequences used were: sense (5’-AAC CTA CAC AAA 
GTT ATA GTC AAC ACA CCC ACC GGT GTT TCG TCC TTT CCA CAA G-3’) 
and antisense (5’-CGG CGA AGC TTT TTC CAA AAA ATG GGT GTG TTG ACT 
ATA ACC TAC ACA AAG TTA-3’).  In this case, the A35R target sequence used 
to design siRNAs was (5’-AAT GGG TGT GTT GAC TAT AAC-3’).  The negative 
control siRNA duplexed sequence was provided by Ambion, and was described 
as a sequence that has limited sequence similarity to known genes.  For this 
experiment, cells were transfected with indicated ng amount of DNA by using 
Lipofectamine 2000 (Invitrogen).  At 24 h post-transfection, medium was 
aspirated and cells were infected with MVA (MOI = 5).  After the 1 h absorption 
period, medium was exchanged, and cellular monolayers were incubated in 
EMEM containing 1% FCS for 6 h.  Cytoplasmic and nuclear proteins were 
extracted as described below. 
 
Conditions for virus infections.   
Subconfluent 293T cell monolayers in 6-well plates were either mock-
infected or infected with either WR, MVA or MVAΔA35R at 10 plaque forming 
units (PFU)/cell, unless otherwise indicated.  During this absorption phase, 
cellular monolayers and viruses were incubated in EMEM containing 1% FCS.  
After a 1 h incubation at 37°C, virus-containing medium was removed, and 
infected-cell monolayers were incubated in fresh, complete medium.  In 
experiments where the activated form of ERK2 was detected, cells were instead 
incubated in medium containing 1% FCS for 24 h before infection, during the 
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absorption stage of infection, and for the duration of infection.  Infections 
proceeded for indicated amounts of time, and cytoplasmic and nuclear proteins 
were extracted as described below.   
In order to test the effect of silencing a viral gene during infection, 293T 
cells were transfected with a pool of siRNAs (Dharmacon) via the Dharmafect1 
transfection reagent.  Twenty-four hours post transfection, the cells were infected 
at an MOI of 5 for four to six hours.   
 
Immunoblotting of cytoplasmic-extracted proteins.   
For all experiments, infected cellular monolayers were dislodged by 
scraping.  Next, cells were collected by centrifugation (30 sec at 10,000 x g).  
Supernatants were removed, and cells were lysed, and cytoplasmic proteins 
were collected as described previously (Gedey et al., 2006).  The protein 
concentration of each sample was determined by using the BCA assay (Pierce).  
An equivalent amount of protein from each sample was loaded into separate 
wells of SDS-12% polyacrylamide gels. 
Proteins were separated electrophoretically and then transferred to a 
polyvinyl difluoride membrane (PVDF; Millipore).  Membranes were incubated in 
blocking buffer (TBS containing 5% milk and 0.1% Tween-20) for at least one 
hour.  Next, membranes were incubated at 4°C overnight in TBS-T (TBS 
containing 0.1% Tween-20 and 0.5% milk) containing the primary antibody 
below. After washing membranes in TBS-T to remove unbound primary 
antibodies, blots were incubated with secondary antibody consisting of either 
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horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:10,000; Fisher 
Scientific).  The antigen-antibody reactions on each immunoblot (IB) were 
detected by using chemilluminescence and autoradiography.  The Pierce 
Supersignal West Pico substrate was utilized, according to the manufacturer’s 
directions.  For IBs detecting A35R Femto (Pierce) substrate was used.  Primary 
antibodies included: rabbit anti-phospho-ERK1/2 antiserum (1:1000; Santa Cruz 
Biotechnology), which interacts with the phosphorylated form of ERK2 and the 
highly similar ERK1 protein; rabbit anti-ERK1/2 antiserum (1:1,000; Santa Cruz 
Biotechnology), which recognizes the ERK2 and highly similar ERK1 protein; 
rabbit A35R (1:5000; Cell Signaling).  
 
Gel electromobility shift assays (EMSAs) of nuclear-extracted proteins.   
The method for isolating nuclear proteins from virus-infected cells was 
described previously (Gedey et al., 2006).  The concentration of protein in each 
sample was determined by using the BCA Protein Assay Kit (Pierce).  Five µg of 
each extract was incubated with 0.35 pmol of 32P-labeled double-stranded 
oligonucleotides containing binding sites for the NF-κB transcription factor 
(Promega) in Gel Shift Assay System Binding buffer (Promega) as per 
manufacturer’s directions.  Some reactions also included excess molar amounts 
of non-radiolabeled oligonucleotides that either contained or lacked NF-κB 
binding sites, or 1 µg monoclonal anti-p65 antiserum (Santa Cruz Biotechnology).  
Following incubation, reactions were resolved electrophoretically in a 6% 
acrylamide gel (Invitrogen) under non-denaturing conditions, using TBE buffer.  
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Afterward, the gels were dried onto filter paper, exposed to a phosphorimager 
plate (Molecular Devices), and images were developed and analyzed using the 
ImageGauge and ImageReader programs, respectively (Fuji). 
 
Luciferase reporter assay.  
To test the effect of ectopic expression of viral genes outside the context 
of an infection on MVA-induced NF-κB activation, cells were co-transfected 50 ng 
pRL-null, 450 ng pNF-κBluc, and 750 ng a plasmid from the VV-expression 
library. The cells were harvested 24 h post-transfection by scraping, collected by 
centrifugation (30 sec at 14,000 x g), and resuspended in passive lysis buffer 
(Promega).  The resultant lysates were assessed for luciferase activities as 
described previously (Shisler and Jin, 2004). All assays were performed in 
triplicate.  For each experimental point, firefly luciferase activity was divided by 
sea pansy luciferase activity to correct for differences in transfection efficiencies.  
Resultant ratios were averaged and normalized to the appropriate control cells 
(mock-infected cells or cells co-transfected with pcDNA3.1, pNF-κBluc and pRL-
null).  The value for the control cells was taken as 1.  Results were displayed as 
relative fold change in luciferase activity as compared to either mock-infected 
cells or pcDNA3.1-transfected cells.  Statistical significance was determined by 
using the Student’s t-test.  
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Reverse-transcriptase (RT)-PCR.   
RT-PCR was used to monitor the extent of siRNA down regulation of 
specific viral transcripts.  Subconfluent 293T cellular monolayers in 24-well plates 
were transfected with a solution containing siRNA molecules specific for 4 
different regions of a vaccinia mRNA by using Dharmafect reagent 1 (Thermo 
Fisher), as listed above.  Cells were transfected with siRNA duplexes and 
subsequently infected with MVA as described above.  At 6 h post-infection, cells 
were harvested by scraping and collected by centrifugation.  Total RNA was 
isolated from cells using the RNeasy kit (Qiagen) according to the manufacturer’s 
protocol.  1 µg of the total RNA from each sample was reverse transcribed into 
single-stranded cDNA by using Superscript II reverse transciptase (Invitrogen) 
and oligo d(T) primers (Integrated DNA Technology) in a 20 µl reaction mixture, 
according to manufacturer’s directions.  The conditions for the reverse 
transcription of RNA to cDNA were: 25°C for 5 min, 42°C for 60 min and 70°C for 
15 min.  Next, 10 µl of each reaction were transferred to new tubes and PCR 
amplified for either the cellular GADPH gene or for a particular MVA ORF.  The 
primers used for amplification are listed below.  For the amplification of the 
GAPDH, E3L, C11R, E7R, A35R, or A ORF L genes, the PCR conditions were 
95°C for 45 s, 58°C for 30 s, and 72°C for 90 s for 20 cycles.  For the remaining 
genes (F ORF A and C ORF B) the PCR conditions were 95°C for 45 seconds, 
54°C for 30 seconds, and 72°C for 90 seconds for 20 cycles.  A portion of each 
reaction was analyzed by agarose gel electrophoresis, and amplicons were 
stained with ethidium bromide to visualize the PCR reaction products. 
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The following sets of forward (for) and reverse (rev) primers were used for 
the cDNA PCR amplification. GAPDH: GAPfor (5’-AAG GTC GGA GTC AAC 
GGA TTT GGT-3’) and GAPrev (5’-ACA AAG TGG TCG TTG AGG GCA ATG-
3’), A ORF L: Afor (5’-TCC TTA TCG GCG GTA TCG GTA CAT-3’) and Arev (5’-
AGG ACG GGC TAA CAT TAC GCA T-3’), E7R: E7for (5’-ACT GCT GCA ACA 
ATT CAG ACT CCC-3’) and E7rev (5’-TGC TAC ATG AGT TCC ATG TGC 
GGA-3’), J2R: J2for (5’-TGT GAG CGT ATG GCA AAC GAA GGA -3’) and J2rev 
(5’- TCT CGG TTT CCT CAC CCA ATC GTT-3’), H5R: H5for (5’- TCC TCG TAA 
ACC AGC GGC TAC TAA-3’) and H5rev (5’-TCT ACA GCA GCC ACG CTT TCT 
ACA -3’).   
 
Results 
Identification of known early gene products and ORFs potentially responsible for 
activating NF-κB during virus infection. 
We had illustrated that early protein synthesis was required for MVA-
induced NF-κB activation (Martin and Shisler 2009). Presumably, the expression 
of an individual early viral protein was activating NF-κB either directly or 
indirectly.  Agreeing with this hypothesis, we identified a viral early gene, C11R, 
whose protein product, Vaccinia Growth Factor (VGF), contributed to MVA-
induced NF-κB activation (in submission).  However, the NF-κB activation 
induced by MVA was not wholly due to VGF expression.  We therefore 
considered the possibility that additional viral factors could be involved in MVA-
induced NF-κB activation.   
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To explore this possibility, we employed a plasmid-based expression 
library consisting of 258 unique clones, with each clone representing a single 
known or putative gene (Tscharke, et al 2006).  Open reading frames (ORF) for 
this library were identified by using a predictive software program (McCraith et al. 
2000), and were defined as those of at least 65 codons in length. While our 
previous data showed that early gene products were responsible for MVA-
induced NF-κB activation, all known and putative ORFs in the library were tested 
for the sake of completeness.  The goal was to identify ORFs that, when 
expressed independently of infection, activated NF-κB, reasoning that these 
ORFs may possess this same function during infection.  Of course, this approach 
had limitations: (1) if a heteromeric viral protein complex was responsible for NF-
κB activation, then this approach would not be effective, (2) the NF-κB activating 
property of an ectopically expressed viral protein may not necessarily exist when 
the protein is instead expressed during virus infection, and (3) since no ORFs 
were engineered to possess epitope tags, the faithful expression of each ORF 
could not be monitored. 
293T cells were co-transfected with individual plasmids containing viral 
genetic material and with luciferase reporter plasmids, and cells were assessed 
for the synthesis of NF-κB-controlled luciferase proteins.  If the ectopic 
expression of a viral protein induced NF-κB controlled luciferase activity at least 
five-fold above that observed for vector-transfected cells, then that product was 
considered to have NF-κB activating properties; representative examples of the 
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luciferase assays are shown in Figure 4.1.  Using these parameters, 37 known or 
putative ORFs possessed NF-κB activating properties (Table 1).   
Until recently, approximately two-thirds of vaccinia virus ORFs had been 
studied on a gene-by-gene basis, and individual ORFs were classified as early, 
intermediate or late genes by using approach (Moss 2007).  From these 
published data, we identified ORFs whose expression during an infection 
occurred either early or in the presence of AraC, and were therefore likely to be 
responsible for the virus’s activating phenotype.  These genes included ORFs 
with early promoters (E5R, J2R, J3R, A29L, A35R) or with early/late promoters 
(J6R, H5R) (Table 1).  Similarly, viral genes that are expressed later in infection, 
possess intermediate or late promoters or are susceptible to AraC treatment 
(C8L, I8R, G6R, H7R, D8L, D11L, A22R, A42R, B16R, G8R) were identified 
(Table 1).  Based on our data, these ORFs were not responsible for the MVA 
activating phenotype, and were not studied further.   
Two independent studies were published in which the vaccinia 
transcriptome was characterized by using microarray-based assays (Assarsson, 
E, et al 2008, and Rubins et al 2008).  These assays identified the temporal 
expression of six ORFs in Table 1: F15L, E7R, G9R, H6R, B18R and WR012.  
The F15L and H6R ORFs were reported to be expressed early in infection for 
both experimental systems (Assarsson, E, et al 2008, and Rubins et al 2008).  
Between these two studies, there was inconsistent or incomplete data for the 
temporal expression of the E7R, G9R and B18R ORFs (Table 1).  For the sake 
of completeness, we decided to continue studies with the E7R, G9R and B18R 
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ORFs as genes that could be responsible for virus-induced NF-κB activation.  As 
shown in Table 1, there were 9 putative ORFs that activated NF-κB: A ORF L, 
C9.5L, E ORF E, I ORF A, C ORF B, C ORF A, F ORF A, A ORF Q and B ORF 
F.  It is unknown when or if these putative genes are expressed during a vaccinia 
infection.  To be thorough, these putative ORFs were also considered as genes 
that could potentially activate NF-κB during MVA infection. 
 
siRNA downregulation of the E7R or A35R ORFs decreases MVA-induced ERK2 
phosphorylation and NF-κB activation. 
 Two reports have demonstrated the successful use of siRNA to decrease 
the expression of individual vaccinia ORFs during infection (Dave et al 2006 and 
Valderrama et al 2006).  Furthermore, we used siRNA previously to 
downregulate the expression of the C11R gene (in submission).  Thus, to further 
investigate the role of an additional individual ORF in MVA-induced NF-κB 
activation, we down-regulated the expression of candidate viral genes by using 
siRNAs.  If MVA-induced ERK2 activation was decreased in these siRNA-
containing cells, then the down-regulated gene of interest was considered 
responsible.   
The down-regulation of transcription for most ORFs did not affect MVA-
induced ERK2 activation (data not shown).  A typical null change in phenotype is 
depicted in Figure 4.2.  Phospho-ERK2 levels were similar in MVA-infected cells 
that were either untransfected or transfected with siRNAs specific for either the 
J2R or H5R ORFs prior to infection.  Levels of unmodified ERK1 and ERK2 
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proteins were likewise unaffected by the presence of siRNAs, indicating that the 
presence of siRNAs and the transfection process itself did not alter ERK1/2 
protein synthesis or stability.  For all experiments, a duplicate set of cells was 
manipulated in parallel.  To assess the effectiveness of the siRNA-mediated 
silencing, the presence of viral transcripts from these cells was assayed by RT-
PCR with primers specific for an individual ORF.  As shown in Figure 4.2, the 
intensity of the bands representing the J2R and H5R amplicons was visibly 
decreased when cells were pre-treated with J2R- or H5R-specific siRNAs in 
comparison to cells not receiving siRNAs.  The differences in levels were not due 
to inadequate technique, since the control GAPDH was PCR amplified in similar 
amounts in all samples.  Further, the presence of siRNAs did not affect the 
transcription of other, non-targeted viral ORFs (data not shown). 
The presence of siRNAs against two different vaccinia ORFs (E7R and 
A35R) affected MVA-induced ERK2 phosphorylation (Figure 4.3A and C).  As 
shown in Figure 4.3A, phospho-ERK2 proteins were slightly more abundant in 
lanes containing lysates from MVA- versus mock-infected cells.  If, instead, 
siRNA specific for the E7R ORF was present during infections, phospho-ERK2 
was no longer detected (Figure 4.3A).  This effect was specific since the 
presence of siRNAs specific for other ORFs (namely A ORF L) did not affect 
MVA-induced ERK2 activation.  Decreased phospho-ERK2 was not due to global 
protein degradation as both ERK1 and ERK2 levels were similar in all cellular 
lysates.  Amplicons specific for either A ORF L or E7R were greatly decreased 
with siRNA treatment, inferring that siRNA down-regulation of these ORFs did 
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occur (Figure 4.3B).  The inability to amplify these ORFs was not due to 
degraded RNA, since GAPDH amplicons were detected from all samples.   
Similar trends were observed when cells instead were transfected with 
siRNA specific for the A35R ORF (Figure 4.3C); phospho-ERK2 levels were 
lower than those observed for MVA-infected cells receiving no siRNAs.  Since 
antiserum recognizing the A35 protein was available, the effect of A35R-specific 
siRNAs on A35R expression was detected by using immunoblotting instead of 
RT-PCR.  As shown in Figure 4.3C, A35 protein levels were decreased in 
infected cells pre-treated with A35R siRNAs versus cells pre-treated with E3L-
specific siRNAs, or infected cells without siRNAs.  RT-PCR was utilized to 
assess the silencing of each gene in this particular assay (Data not shown). To 
directly measure of the effect of diminishing E7R or A35R transcription on MVA-
induced NF-κB activation, nuclear translocation was assessed by EMSAs (Figure 
4.4A).  Similar to previous results, MVA infection resulted in activation of NF-κB, 
as denoted by the presence of a band with an increased intensity as compared to 
that observed with mock-infected cells.  In this experiment, a non-specific higher 
molecular weight band was also present, in mock- and MVA-infected cells.  The 
incubation of cells with siRNA specific for the A ORF L gene did not dramatically 
affect MVA-induced nuclear translocation, as evidenced by the presence of a 
band of similar intensity to that observed from MVA-infected cells, indicating that 
the siRNA transfection process did not affect MVA-induced NF-κB activation.  In 
contrast, the presence of siRNAs specific for C11R, E7R, or A35R decreased the 
intensity of the NF-κB-containing band. While NF-κB was still active in cells 
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incubated with C11R or E7R siRNAs, the levels were lower than that observed in 
mock-infected cells.  Noticeably, the presence of A35R-specific siRNAs had the 
greatest inhibitory effect. 
We utilized a second, independent method of gene silencing to verify that 
down regulation of one gene, A35R, indeed altered the NF-κB activating 
phenotype of MVA.  For this experiment, an siRNA expression cassette was 
utilized to inhibit A35R transcription, and NF-κB activation was measured by 
EMSAs.  Results are shown in Figure 4.4B.  Similar to Figure 4.4A, when 
infected cells were pre-incubated with either 250 ng or 100 ng A35R SEC siRNA, 
the NF-κB-containing band was decreased.  However, MVA-induced NF-κB 
nuclear translocation still occurred when cells were transfected with 25 ng siRNA.  
If cells were instead pre-treated with siRNAs that were a random sequence 
predicted to not interact with A35R, the NF-κB-containing band was still present, 
inferring that the inhibition observed was specifically due to the presence of the 
A35R siRNA.   
 
Deletion of A35R does not result in a decrease of MVA-induced NF-κB 
activation. 
Of the two additional viral genes identified as being capable of affecting 
NF-κB activation in MVA-infected 293T cells, A35R was chosen for further study 
as it produced a more profound effect on both ERK1/2 phosphorylation and NF-
κB activation.  To this end, we used a deletion mutant virus lacking the A35R 
gene, MVAΔA35R.  We either mock infected or infected 293T cells with MVA or 
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MVAΔA35R at an MOI of 10 for four hours.  Surprisingly, unlike the results seen 
when A35R was silenced, the deletion of A35R seemed to have no effect on 
MVA’s ability to induce either pathway.  As shown in Figure 4.5, no difference 
was observed between MVA and MVAΔA35R in measuring ERK1/2 
phosphorylation.  Furthermore, the degree of NF-κB activation in MVAΔA35R-
infected cells was comparable to the activation seen in MVA-infected cells 
(Figure 4.5). 
 
Discussion 
Modified vaccinia virus Ankara infection, unlike wild-type vaccinia strains, 
activates the cellular NF-κB transcription factor (Gedey et al., 2006, Oie and 
Pickup 2001).  Previously we had shown that expression of the viral early gene, 
C11R, contributed to both MVA-induced ERK1/2 and NF-κB activation.  Here we 
found at least one additional viral gene that may enhance this activation during 
an MVA-infection.   
Ectopic expression of E7R was found to induce NF-κB-controlled 
luciferase activity (Figure 4.1A) while silencing of the viral gene resulted in a 
decrease of both ERK1/2 and NF-κB activation in MVA-infected cells (Figure 
4.3). An MVA virus lacking E7R could be used to further characterize the effect 
E7R has on the NF-κB and ERK1/2 pathway, however this has not yet been 
performed.  Presumably, the results would be expected to be in agreement with 
the data seen with silencing of the gene, as was seen when the results when 
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silencing C11R and deletion of C11R from the MVA genome were compared (in 
submission).   
Little is known about the functions of E7, beyond that it is a soluble, 
myristylated protein (Martin et al., 1997).  Yeast-two hybrid analyses identified 
the vaccinia A39 protein, a semaphorin that induces cytokine production in 
human cells (Comeau et al., 1998), as a potential E7 binding partner (McCraith et 
al., 2000).  It is not known if E7-A39 interactions affect MEK/ERK activation.  
Whether the E7 protein affect the same signal transduction pathways as the 
pathway utilized by C11R is also unknown.  E7R gene silencing only partially 
inhibited MVA-induced NF-κB activation, similar to that seen with C11R (in 
submission).  It is doubtful that the E7 and C11 proteins function as a complex 
since each protein possessed NF-κB activation properties when expressed 
independently of infection, and no interactions between these proteins were 
detected when using yeast two-hybrid analyses (McCraith et al., 2000).   
We previously observed that NF-κB remained active in MVA-infected cells 
for an extended period of time (Martin and Shisler 2009).  The promoter 
sequence for E7R resembles that of an early/late promoter (www.poxvirus.org), 
suggesting it is synthesized throughout infection.  There is conflicting data as to 
the time of E7 expression, with two reports identifying E7R transcripts and 
products late in infection (Assarsson et al., 2008, Martin et al., 1997), and one 
report identifying E7R expression early in infection (Rubins et al., 2008).  
Assessing the temporal NF-κB activation profile when cells are infected with a 
mutant MVA virus lacking the E7R ORF will identify the effects of this protein. 
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Like the observations with E7R  (Figure 4.1A) and C11R (in submission), 
overexpression of A35R induced NF-κB activation outside the context of an 
infection (Figure 4.1B).  Further, a V5-tagged version of the protein was 
generated that was able to induce NF-κB controlled luciferase activity when it 
was expressed ectopically as well (data not shown).  Silencing of the A35R gene 
using two separate techniques resulted in a dramatic decrease of both ERK1/2 
and NF-κB activation in MVA-infected cells (Figure 4.3C and 4.4).  Taken 
together, this suggested that A35R was an activator of NF-κB and ERK2.  
Consequently, we predicted that deletion of the A35R gene would result in a 
virus that would no longer activate these cellular pathways.  However, when we 
tested a deletion mutant virus lacking A35R (MVAΔA35R), we observed the 
opposite.  Infection with MVAΔA35R not only induced ERK1/2 and NF-κB 
activation, it appeared to activate them to the same level as seen in MVA 
infections (Figure 4.5).  We initially suspected that either the A35R gene had not 
been deleted in the virus or that the mutant virus had been contaminated with the 
parental MVA strain.  To address this, we performed RTPCR, however no A35R 
mRNA was detected in cells infected with MVAΔA35R (data not shown). As 
MVAΔA35R was not generated in our lab, we wondered if the parental MVA 
strain used to produce MVAΔA35R was in someway altered compared with the 
MVA strain with which we worked and could therefore, induce NF-κB to a 
different degree.  If the parental MVA was a stronger inducer of NF-κB activation 
than the MVA used in our studies, it could be possible that the MVAΔA35R virus 
did not induce either ERK1/2 or NF-κB to the same degree as its parental MVA 
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strain.  To test this, we propagated the parental MVA virus of MVAΔA35R and 
tested for its ability to induce NF-κB and ERK1/2 in comparison to the MVA we 
used and to MVAΔA35R.  We found that there was in fact a difference between 
the MVA we used in our lab and the parental strain of MVAΔA35R, as the MVA 
we possessed was a stronger inducer of NF-κB activation, suggesting that 
deletion of A35R enhanced NF-κB activation (data not shown).  Why deletion of 
the gene gives such vastly different results than those seen with silencing of the 
gene is not known.  The sequence for a putanitive ORF, A ORF M, has a 160 nt 
overlap with the sequence encoding A35R (www.poxvirus.org).  Therefore it 
could be that the partial deletion of the A ORF M sequence could be contributing 
to MVAΔA35R-induced NF-κB activation.  However, this seems unlikely as A 
ORF M was not identified in our screen of viral ORFs capable of inducing NF-κB, 
and furthermore, it is unknown if the A ORF M sequence encodes a functional 
protein. 
Recent insights have been published into the role of A35 during an in vivo 
infection.  The A35 protein is a soluble protein that is expressed early in infection 
(Roper 2006) which localizes to endosomes in infected antigen presenting cells 
(Rehm et al., 2010).  Deletion of the A35R ORF from a wild-type strain of 
vaccinia virus resulted in a mutant virus with an attenuated phenotype in vivo 
(Roper 2006), inferring that the A35 protein may regulate immune responses.   
More recent studies have classified A35 has being immunosuppressive by 
interfering predominantly with the antigen presentation of MHC class II to T cells 
(Rehm et al., 2010).  Furthermore, the deletion mutant MVAΔA35R virus was 
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found to be more immunogenic than the parental MVA in infected mice (Rehm 
and Roper 2010). How this relates to the NF-κB activation state at the cellular 
level, particularly in fibroblasts cells similar to the cells used in this study, is 
unclear and should the focus of future studies.  
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Figures 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Ectopic expression of E7R and A35R induces NF-κB activation 
in 293T cells.  (A) and  (B) 293T cells were transfected with the luciferase 
reporter plasmids, pNF-κBluc and pRL-null and either 750 ng of pcDNA3.1 (-) or 
plasmids containing a predicted ORF from the vaccinia virus genome.  At 24 h 
post-transfection, the cells were lysed in passive lysis buffer and luciferase 
acitivity was measured.  The ratios of firefly to sea pansy luciferase activities 
were normalized to that of mock-infected cells, whose value was set to 1. 
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Figure 4.2. siRNA-induced silencing of J2R and H5R does not affect MVA-
induced ERK1/2 phosphorylation. 293T cells were separately transfected with 
a solution containing siRNA molecules specific for four different regions of either 
J2R or H5R at the indicated molarities.  Alternatively, a separate set of cells 
received no double-stranded RNA molecules.  At 24 h post-transfection, cellular 
monolayers were either mock-infected or infected with MVA (MOI=5) and 
harvested 6 h post-infecteion.  All transfections and infections were performed in 
duplicate.  (A) One set of infected cells was subsequently lysed in CE buffer, and 
10 µg of each cytoplasmic extract was analyzed for the presence of the 
phosphorylated and unphosphorylated forms of the ERK1/2 proteins. (B) For the 
alternate set of cells, the cells were lysed and total RNA was extracted.  Total 
RNA was reverse transcribed into cDNA.  The cDNA was then PCR amplified by 
using primers specific for either GAPDH of for the indicated viral ORFs.  A 
portion of each PC reaction was analyzed by agarose gel electrophoresis, and 
amplicons were visualized by ethidium bromide stain. 
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Figure 4.3. siRNA silencing of the E7R and A35R gene diminishes MVA-
induced ERK1/2 activation.  293T cells were transfected with chemically 
synthesized siRNA for 24 h.  Cells were mock-infected or infected with MVA 
(MOI=5) and harvested 6 h later. (A) Cytophasmic extracts were analyzed by 
immunoblotting, probing the blots with antibodies against the phosphorylated 
form of ERK1/2 (p-ERK1/2).  The blot was then re-probed with antiserum against 
ERK1/2. (B) mRNA levels of individual virual and cellular genes were analyzed 
via reverse-transcriptase PCR (RT-PCR), in which 1 µg of total RNA per sample 
was used.  For the reverse-transcription reaction, oligo d(T) was used as a 
primer to generate cDNA.  Then, primers specific for individual genes were used  
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Figure 4.3 (cont.) 
in subsequent PCR reactions.  A portion of each PCR reaction was analyzed by 
electrophoresis in a 1% agarose gel containing ethidium bomide.  Images were 
captured and inverted.  (C) 293T cell monolayers were transfected with siRNA 
targeting either A35R or E3L.  24 h post-transfection, the cells were infected with 
MVA (MOI=5) for 6 h.  Cellular extracts wer harvested and analyzed via 
immunolblotting.  The blots were probed with antibodies specific for the 
phosphorylated for of ERK1/2 (p-ERK1/2) and then reprobed with antibodies 
against total ERK1/2. 
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Figure 4.4.  Silencing of the E7R or A35R gene reduces MVA-induced NF-
κB activation.  293T cells were transfected with either (A) chemically 
synthesized siRNA specific for either C11R, E7R, A35R, or E3L, or (B) with 
regular medium or medium containing the indicated amounts of the A35R SEC or 
an SEC that is not predicted to downregulate A35R (NC siRNA).  24 h post-
transfection, celluslar monolayers were either mock-infected or infected with 
MVA (MOI=5) and harvested 6 h post-infection.  Infected cells were lysed and 
nuclear proteins were isolated.  Next, 5 µg nuclear-extracted proteins were 
incubated with a [32P]ATP labeled oligonucleotide containing a consensus NF-
κB binding site.  Samples were analyzed via an electromobility shift assay.  The 
location of mobility-shifteed bands containing NF-κB is indicated by an asterisk.  
Some reactions contained nuclear extracts from MVA-infected cells in which anti- 
NF-κB antibodies (p65 Ab) or non-radiolabeled oligonucleotides either lacking 
(AP1) or containing (NF-κB) binding sites were present. 
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Figure 4.5.  MVAΔA35R induces ERK1/2 and NF-κB activation. 
293T cells were either mock-infected or infected with either MVA or MVAΔA35R 
(MOI=5).  At 4 h post-infection cells were lysed, and (A) cytoplasmic extracts 
were analyzed by immunoblotting, using antibodies against the phosphorylated 
form of ERK1/2 (p-ERK1/2).  The blot was re-probed with antibodies against 
ERK1/2.  (B) Nuclear extracts were incubated with a [32P]ATP-labeled 
oligonucleotided containgin a consensus NF-κB binding site.  Antibody against 
the p65 subunti of NF-κB was included where indicated (“p65 Ab”).  The reaction 
mixture was analyzed by electrophoresis in a 6% gel, under non-denaturing 
conditions.  An asterisk (*) indicated NF-κB bound to proble. 
 
 
 131 
TABLE 4.1.  Vaccinia strain WR open reading frames that induced NF-κB-
mediated luciferase activity when expressed ectopically in 293T cells1 
Name or 
nucleotide 
location in 
WR 
genome2 
Copenhagen-
based name 
Classification 
and 
reference3 
 
Classification 
by 
microarray4 
Initial 
time of 
detection 
(h pi)5 
Properties 
009 C11R E   E 0.5 EGF-like growth 
factor 
019 C9L E   L 1 Host range; 
ankyrin protein 
020 C8L L L 2 Hypothetical 
12 WR012 ND E 2 Zinc finger like; 
apoptosis 
054 F15L ND E 1 Hypothetical 
061 E5R E   L 0.5 Hypothetical 
063 E7R L   E 4 Myristyl protein 
077 I8R I  E 2 virion NPH II 
084 G6R L   E 2 Hypothetical 
086 G8R I  L 4 virus late TF, 
VLTF-1 
087 G9R ND E 4 Myristyl protein 
094 J2R E L 0.5 Thymidine kinase 
095 J3R E   L 0.5 Vaccinia 
methyltransferase 
098 J6R E/L   E 0.5 RNA Polymerase 
subunit 
103 H5R E/L E 0.5 Late TR/envelope 
protein 
104 H6R ND E 2 DNA 
topoisomerase 
type I 
105 H7R L E 4 Hypothetical 
113 D8L L   L 4 IMV membrane 
protein 
116 D11L L   L 2 virion NPH I 
142 A22R L   E 2 Holliday junction 
resolvase 
152 A29L E   E 2 RNA polymerase 
subunit 
158 A35R E   E 0.5 Immune 
modulator 
167 A42R L   L 6 profilin homolog 
190 B8R E   E 0.5 IFNγ secreted 
receptor 
197 B16R L   E 4 soluble IL-1β 
receptor 
199 B18R E   L 1 Ankyrin protein 
F142514-
142780 
A ORF L ND ND ND Hypothetical 
R010738-
011451 
C9.5L ND ND ND Hypothetical 
F056234-
056431 
E ORF E ND ND ND Hypothetical 
F062750-
062983 
I ORF A ND ND ND Hypothetical 
F015300-
015524 
C ORF B ND ND ND Hypothetical 
F019414-
019623 
C ORF A ND ND ND Hypothetical 
F031867-
032070 
F ORF A ND ND ND Hypothetical 
R153492-
153809 
A ORF Q ND ND ND Hypothetical 
R175451-
175678 
B ORF F ND ND ND Hypothetical 
1293T monolayers were co-transfected with pRL-null, pNF-κBluc and the indicated ORF.  
At 24 h post-transfection, cells were harvested and lysates were assayed for luciferase 
activities.  The ORFs listed in Table 1 induced luciferase activity at least 5-fold above that 
observed for vector-transfected cells. 
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Table 4.1 (cont.) 
2Sequence based on vaccinia strain western reserve (WR) genome (www.poxvirus.org) 
3Classification when characterizing individual ORFs by non-microarray-based methods; E 
= early gene, I = intermediate gene, L = late gene.  Primary literature containing this data 
is indicated in parenthesis. 
4Gene classification as reported in Rubins et al., 2008.  E = early, L = late 
5Time of expression, in h post-infection, as reported in Assarsson et al., 2008.  
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Chapter V: Summary and Future Directions 
 
Summary 
The focus of the work presented here was to investigate the molecular 
mechanism behind MVA-induced NF-κB activation.   Much interest has been 
directed toward the MVA in recent years as a potential vaccine vector, as is 
illustrated with the work being done towards a malaria vaccine using MVA 
(Gilbert, et al. 2006).  Historically, MVA was one of the vaccinia strains used 
during the WHO smallpox eradication campaign in the mid-twentieth century.  
Compared to the wild type vaccinia (VACV), MVA is not as immunogenic, as 
vaccination with MVA requires boosters to achieve a similar protective response.  
On the positive side, MVA is unable to replicate in human cells, thereby 
eliminating most of the hazardous side effects associated with VACV, such as 
vaccinia eczema and vaccenimia.  Furthermore, infection with MVA results in the 
activation of the pro-inflammatory NF-κB pathway, which would theoretically 
affect MVA’s immunogenicity.  
Previous work had shown that infection with MVA activated NF-κB in 293T 
cells (Oie and Pickup 2001).  The work in this dissertation proved that it was the 
expression of viral genes early during the viral lifecycle that induced both the NF-
κB and MEK/ERK pathway in these cells (Martin and Shisler 2009).  Because 
MVA as a temporal life cycle, it is possible to block the various steps of the life 
cycle and prevent further downstream events from occurring.  In this way, early 
viral gene expression was shown to be the required event for inducing NF-κB 
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activation.   Blocking all events upstream, such as viral binding, entry, and early 
gene transcription, did not result in NF-κB activation, while blocking events 
occurring after early gene translation, namely DNA replication and intermediate 
gene translation, had no effect on MVA-induced NF-κB activation.   
Upon investigation of which specific early viral gene products were 
involved in the activation of NF-κB, the early viral C11R protein, Vaccinia Growth 
Factor (VGF), was identified.  VGF is a conserved poxvirus protein that is 
homologous the human epidermal growth factor (Brown, et al., 1985).  As such, it 
is a soluble protein that is secreted from the cell and has been shown to interact 
with EGFR.  VGF was shown to contribute to NF-κB activation both when it was 
expressed ectopically and during an MVA infection (in submission). MVAΔC11R, 
a deletion mutant virus lacking the C11R gene and therefore no longer 
expressing VGF, had reduced levels of phosphorylated ERK1/2 and NF-κB 
activation compared to the levels seen in MVA-infected cells.  Two additional 
early viral proteins, the E7 and A35, were also shown to play potential roles as 
silencing each of them individually resulted in decreased NF-κB activation in 
MVA-infected cells.  
Many questions remain as to why MVA and the wild type strains of 
vaccinia virus encode proteins that can activate NF-κB.  NF-κB activation is not 
detectable during infections with the wild type vaccinia, suggesting that signaling 
through NF-κB is not desirable for the virus. So why the VACV encodes multiple 
genes whose products contribute to NF-κB is not inherently obvious.  And in fact, 
vaccinia encodes NF-κB inhibitors, including the M2L gene, whose product 
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inhibits NF-κB activation via modulation of the MEK/ERK pathway.  A number of 
viruses do encode genes whose products can induce NF-κB, such as HIV and 
various herpesvirus (Hiscott et al., 2006) and are therefore able to benefit form 
NF-κB activation.  Whether NF-κB activation is beneficial to the lifecycle of MVA 
is unknown.  Perhaps more importantly, how NF-κB activation affects the 
immunogenicity of MVA is not understood.  If NF-κB signaling contributes to the 
immunogenicity of MVA, then expression of the genes identified in this work is 
beneficial for using MVA as a vaccine vector.  However, if NF-κB signaling 
negatively impacts MVA immunogenicity, then deletion of the genes discussed 
here could result in an improved MVA vaccine vector.  Regardless, the 
identification of C11 and its contribution to NF-κB activation, and the potential 
contributions of E7 and A35 further, our understanding of the interplay between 
the virus and the host cell. 
 
Future Directions 
 MVA-induced NF-κB activation in 293T cells is due to the expression of 
specific viral genes expressed early during infection (Martin and Shisler 2009).  
Specifically, we were able to show that one of these early genes, C11R 
contributed to MEK/ERK and NF-κB activation during an MVA infection, however 
the exact molecular pathway has not been determined.  The protein product of 
the C11R gene is a homologue of the Epidermal Growth Factor, the Vaccinia 
Growth Factor (VGF), and has been shown to bind to the Epidermal Growth 
Factor Receptor (EGFR).  While EGFR contributes (Fig 3.2) to MVA-induced NF-
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κB and MEK/EKR activation, the downstream canonical Ras and Raf proteins 
were not involved (Fig 3.3).  The effectors downstream of EGFR in VGF signaling 
needs to be determined to better understand not only the pathway leading from 
EGFR to NF-κB activation, but to also understand the potential role NF-κB 
activation serves during an MVA infection.  At this point, it is unclear how the 
activation of NF-κB affects the virus in vivo.  Characterizing MVAΔC11R behavior 
in mice and specifically comparing the virus’ abiltity to protect mice from vaccinia 
challenge would shed light on whether NF-κB contributes to or limits MVA 
immunogenicity. 
 In addition to C11R, the E7R and A35R genes were also identified as 
contributing to MVA-induced NF-κB activation.  To confirm the role of the E7 
protein during an MVA-infection, an E7R deletion mutant MVA virus needs to be 
constructed and tested for it’s ability to activate the MEK/ERK and NF-κB 
pathways.  While we would expect that deleting the E7R gene from the viral 
genome would result in similar findings as where observed when E7R was 
silenced via chemically synthesized siRNA (Figure 4.4A), this would not 
necessarily be the case, as the results of deleting A35R from the genome did not 
match the results obtain when A35R was silenced (Figure 4.5).  Nevertheless, a 
MVAΔE7R virus needs to be tested.  If MVAΔE7R virus did not induce or had 
reduced MEK/ERK or the NF-κB activation, then the signaling pathway would 
need to be determined next.  To that end, an epitope-tagged version of the E7 
protein could be used to test for cellular localization and look for potential 
interactions with cellular molecules.  Further characterizations of the virus would 
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be similar to that of MVAΔC11R.  A35R was also identified as having NF-κB 
activating properties (Figure 4.1B), however infection of 293T cells with the 
deletion mutant MVAΔA35R virus still resulted in both MEK/ERK and NF-κB 
activation (Figure 4.5).  Investigation into the apparent contradiction of these 
results would help to define A35’s role during a viral infection.    
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